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ABSTRACT 
Genetic variability in genes encoding drug metabolizing enzymes, transporters and targets are 
known to be the main factors of inter-individual differences in therapeutic outcome. Genetic 
factors are estimated to be responsible for about 15-30% of inter-individual variation in drug 
disposition and response. Single-nucleotide polymorphisms (SNPs) are the most prevalent 
class of genetic variation that could explain the variability in drug efficacy and undesired side 
effects for patients. 
The aims of this study were to develop and evaluate the performance of robust and high 
throughput techniques for genotyping ten polymorphisms related to anticancer drugs and ten 
polymorphisms related to cholesterol lowering drugs. SNaPshot minisequencing and high 
resolution melt analysis (HRM) genotyping panels were developed, optimized, and their 
performances were evaluated and compared. SNaPshot minisequencing systems were 
developed and successfully optimized for the genotyping of ten SNPs associated with 
anticancer drug therapy, and ten SNPs associated with cholesterol lowering drugs. These 
systems were used to genotype the selected SNPs in 130 healthy Cape Admixed participants 
residing in Cape Town, South Africa. Population genetics data obtained for the studied SNPs 
were analysed using several statistical analysis software tools. Important population genetic 
parameters were calculated. Among others, allelic and genotypic frequencies were 
determined and compared with other populations in the world. 
High resolution melt analysis (HRM) genotyping panels were developed, optimized and their 
performance were evaluated and compared to the SNaPshot assays. HRM was explored as an 
alternative inexpensive and rapid methodology to genotype five SNPs related to anticancer 
therapy and five SNPs related to cholesterol lowering therapy (statins). Unlike the SNaPshot 
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assays, rigorous optimization was required for the detection heterozygous genotypes via 
HRM. 
Both assays were validated using direct sequencing and compared to each other. The HRM 
system is a closed tube, cheap and (theoretically) rapid method for identifying genetic 
variations. HRM was however found to be more time consuming, needed further 
optimization, primer redesigning and more evaluation.  
The developed genotyping systems could be further validated using clinical samples from 
patients. This could help in optimizing drug therapy for cancer and cholesterol treatment. 
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Chapter One 
Literature review 
 
1.1. Introduction 
The improvement of new methods for high-throughput single nucleotide polymorphism 
(SNP) analysis is one of the most exciting areas in genetic studies (Quintáns et al. 2004). 
Recently, countless methodologies for high-throughput SNP analysis have been developed 
such as: FRET analysis by real time PCR, DNA microarrays, Pyrosequencing, MALDI-TOF 
spectrometry and TaqMan probes or Molecular Beacons (Carracedo et al. 1998; Syvänen 
2001). The application of these methodologies has revolutionized many of the biomedical 
sciences. However, it has had a major influence when applied to the molecular study of 
human genetic variations (Carracedo et al. 1998).  
There is increasing interest in SNP typing due to their application in pharmacological 
response and genetic disease diagnosis (Evans and Relling 1999). It is well known that 
individuals’ DNA differs which makes some people more susceptible to specific diseases 
than others (Pennisi 2007). It has long been recognized that genetic variations in drug 
metabolizing enzymes, transporters and targets underlie the inter-individual variability in 
drug response. These differences that influence drug response might be due to age, sex, body 
weight, nutrition, organ function, infections, concomitant medication, environmental factors, 
and genetic makeup (Sadée and Dai 2005; Jacobs 2014). Hence, the goal of both 
Pharmacogenetics and Pharmacogenomics (PGXs) is to carefully study these variations to 
improve drug efficacy (Lee et al. 2005)with the ultimate aim to individualize therapy by 
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choosing the right drug  for each patient by classifying them into genetically definable groups 
that have similar drug responses (Kalow 2002). The advantage of studying human genetics is 
the discovery and description of the genetic contribution to many human diseases. This is a 
motivation for increasing studies to define the contribution of several genes to the 
development of diseases such as cancer, heart disease, and diabetes (Pennisi 2007).  
Africa has a high level of genetic diversity, but in spite of this diversity, population genetic 
studies are limited (Henry et al. 2008). South Africa is the home of native and immigrant 
population groups (Benjeddou 2010).The mix of these different ethnicities led to 
establishment of a unique population called Cape Coloured (Abrahams et al. 2011) which are 
designated here as Cape Admixed. The genomic intermixture in the Cape Admixed can form 
an essential foundation for subsequent pharmacogenetics studies in order to predict 
individualised therapy specially in Africa (Ikediobi et al. 2011). Note, that in this study the 
term “precision medicine” will be used interchangeably with “individualised” or 
“personalised therapy”. 
 
1.2. Human genetic variations 
Human genetic variation is the differences in the occurrence of mutations between the 
genomes of individuals and populations. The genomes of any two individuals differs at 
approximately one in every 1,000 base pairs (Venter et al. 2001) which results in an identify 
of up to 99.9% (Kruglyak and Nickerson 2001). Variation can appear in different ways, it can 
be in a single base pair, insertions/deletions of many nucleotide-long fragments of 
deoxyribonucleic acid (DNA) or loss of entire genes (Pelak et al. 2010). The rate of human 
genetic variation due to differences between populations is modest, and individuals from 
different populations can be genetically more similar than individuals from the same 
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population (Witherspoon et al. 2007). Major variations can be found within populations 
which can provide beneficial information about the histories and backgrounds of humans 
(Cavalli-Sforza et al. 1994). Human genetic variation has a direct influence on a wide range 
of biological and medical disciplines. Thus, the study of human genetic diversity is relevant 
to several research areas including human and population genetics, molecular biology, 
evolutionary biology, biological anthropology, health sciences and clinical medicine 
(Benjeddou 2010).  
 
1.2.1. Insertion and deletion variation  
Insertion and deletion (INDEL) variation refers to a type of genetic variation in which a 
specific nucleotide base pair is added or removed at some location of the DNA molecule 
during replication (Mills et al. 2006). INDELs are widely spread in the genome as they 
encompass a total of 3 million of the 15 million known genetic variants in humans(Mills et 
al. 2006) .There are five types of INDELs, including insertions and deletions of single-base 
pairs, monomeric base pair expansions,  multi-base pair expansions of 2–15 bp repeat units, 
transposon insertions, and  INDELs containing random DNA sequences (Mills et al. 2006). 
 
1.2.2. Short Tandem Repeats variation 
Short Tandem Repeats variation (STRs) are regions of DNA composed of short nucleotide 
sequence (2 to 6 base pairs long) repeated many times (Willems et al. 2014). STRs are also 
considered to be the most polymorphic regions in the human genome, and play a role in 
genetic diseases and have been used in forensics, in determining genetic profiles and 
population genetics. Studies have shown that STRs sites are prone to mutations during DNA 
replication (Willems et al. 2014). 
1.2.3. Single nucleotide polymorphisms  
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Single-nucleotide polymorphisms (SNPs) are the most prevalent class of genetic variation 
amongst people and are a valuable resource for mapping complex genetic traits (Marth et al. 
1999; Reumers et al. 2008). SNPs are introduced by the  substitution of one nucleotide with 
another at a particular locus within the DNA sequence (Simko et al. 2006). On average SNPs 
occur at approximately one in every 1000 bp (Komar 2009). SNPs could appear as bi-, tri-, or 
tetra-allelic polymorphisms. However, as tri-allelic and tetra-allelic SNPs are rare or almost 
do not exist in humans, SNPs are often described as bi-allelic markers (Brookes 1999).  
SNPs in the coding region (cSNPs) can be either, synonymous or nonsynonymous. 
Synonymous SNPs do not affect the protein sequence, while nonsynonymous SNPs change 
the amino acid sequence of a protein and may subsequently change its structure and function 
(Liao and Lee 2010). SNPs in regulatory regions of a gene can result in a disease phenotype 
because they may affect gene splicing, transcription factor binding sites, and other functional 
sites at the transcriptional level (Reumers et al. 2008). The majority of SNPs occur in the 
non-coding region of the human genome where  they do not have direct effect on a phenotype 
(Liao and Lee 2010). Studies have shown that not all SNPs are useful genetic markers. 
However, SNPs found in the promoter and expressed regions have a direct impact on gene 
function and are considered  to be worthwhile molecular markers (Paris et al. 2003). SNPs 
act as biological markers that assist scientists to distinguish genes that are linked to diseases 
(Cargill et al. 1999). 
1.3. Precision medicine and Pharmacogenetics / Pharmacogenomics   
Currently, the terms pharmacogenetics and pharmacogenomics which have so much in 
common are  used interchangeably to refer to studies investigating the contribution of 
inheritance to variation in the drug response phenotype (Weinshilboum and Wang 2006). 
More accurately, pharmacogenetics specifically refers to approaches that are concerned with 
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studying the genetic influence of individual difference to drug responses, identifying 
variations that are caused by hereditary factors (Issa 2002), and uses a patient’s genetic 
information in order to improve and personalise drug treatment (Holm 2008). Conversely, 
pharmacogenomics is defined  as all genes that influence drug responses, and uses genome 
wide analysis to identify such genes and search for novel drug targets (Srinivasan et al. 2009; 
Wu and Fuhlbrigge 2008). Generally, genetic factors are responsible for about 15 to 30% of 
differences in drug metabolism and rarely can account for up to 95% for certain drugs. These 
genetic differences can affect pharmacokinetics and pharmacodynamics (Choi and Song 
2008; Nebert et al. 2008; Benjeddou 2010). Pharmacokinetics describes the process of drug 
transport in the body in terms of its absorption, distribution, metabolism, and elimination 
(Shell 1982; McLeod and He 2012), while pharmacodynamics is defined as the study of drug 
concentration and the pharmacological effects on the body (Craig 1993; Sinnollareddy et al. 
2012). However, the variability in drug response can be due to non-genetic factors, such as 
age, concomitant diseases, food, environment factors and  organ functioning (Choi and Song 
2008; Nebert et al. 2008; Benjeddou 2010).  
The focus of pharmacogenetics studies is pharmacokinetics, while pharmacogenomics 
focuses on how genetic variation is linked to an individual’s pharmacodynamics response 
(Kalow 2006; Weinshilboum and Wang 2006).The promise of  both branches of study is to   
deliver personalised medicine which is based on clinical, genomic, genetic and environmental 
information of each patient (Limdi and Veenstra 2010). Such developments in 
pharmacogenetics and pharmacogenomics studies can be used to define diseases and 
biomarkers. This will lead to a patient-tailored therapeutic drug that hopefully would be more 
effective and will result in fewer adverse drug reactions (Kalow 2002; Oscarson 2003; 
Hedgecoe 2004). Ultimately, it is hoped that by knowing the important genetic variations that 
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exist between racial and ethnic groups, it will be possible to classify patients into low, 
intermediate and high dose groups (Shastry 2006). 
 
1.4. Pharmacogenetics and ethnic background 
Race, ancestry and ethnicity have been identified as major factors in pharmacogenetic 
discovery and improving our understanding of population differences in drug response 
(Urban 2010). This means that the variant that affects a response to a type of drug in one 
ethnic group may not have the same impact in another group, and this is due to gene-gene or 
gene-environment interaction differences (Tate and Goldstein 2004). For example, warfarin 
treatment shows a wide variance among patients of different racial groups, and this variance 
might be due to polymorphisms in the gene encoding for vitamin K epoxide reductase 
complex 1. One example of this is that  heparin and warfarin dosages for Chinese patients are 
lower than those commonly prescribed for Caucasian patients (Daar and Singer 2005). 
Another example is that the cardiovascular  drug BiDil, is recommended for African people 
because as it has low side effects compared with Caucasians (Taylor et al. 2004). 
Understanding ethnic genomic differences in populations is required to improve drug 
treatment and to establish public health policies (Shastry 2006; Suarez-Kurtz 2008b). Africa 
is a widely diverse landscape. Sub-Saharan Africans have the highest human genomic 
diversity in the world, however this diversity is understudied (Tishkoff et al. 2009; 
Benjeddou 2010). South Africa has a wide population diversity as a result of combination of 
different groups from Europe, Asia and Africa (Adhikari 2005; Benjeddou 2010). The unique 
South African Cape admixed population which is distinguished by wide ethnic intermixture 
diversity comprising  about 9 - 11% Asian, 21 - 28% white, 32 - 43% Khoisan and 20 - 36% 
black populations (de Wit et al. 2010; Erasmus et al. 2012). The mixed ancestries in this 
population may help set the foundation for future pharmacogenetics traits studies, in order to 
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predict personalized therapy in diverse populations particularly in Africa (Ikediobi et al. 
2011). This wide ethnic diversity supplies a valuable opportunity to study genomic patterns 
(Conrad et al. 2006). In addition, the complexity in the Admix populations creates an ideal 
situation for exploring the role of genetic ancestry of population, as well as clinical and 
environmental factors on human health(Suarez-Kurtz 2008a; Via et al. 2009). 
 
1.5. Genetic variation and drug response 
Inter-individual differences in drug disposition are substantial reasons for adverse drug 
reactions and deficiency in drug response (Sim et al. 2013). Despite that, genetic variation in 
the human genome plays a main role in variable response to drugs and other xenobiotics 
(Brockmöller and Tzvetkov 2008). Polymorphisms in drug metabolising enzymes, drug 
transporters, drug receptors, and ion channels genes can  lead to adverse drug reactions or can 
change the efficacy of therapeutics (Meyer 2000). Many of the newly identified SNPs could 
play a significant role in the expression level and activity of the corresponding protein 
(Venter et al. 2001). Such polymorphisms once they occur in genes encoding drug 
transporters or drug metabolizing enzymes might change the disposition of the drug, and 
subsequently, its efficacy and toxicity may be affected (Robert et al. 2005).  
 
1.6. Drug transporters 
Transport proteins play an important role in absorption, distribution, and excretion of many 
medications. They play a significant role in drug response, serving as drug targets and 
determining the most effective dose of each drug (Leabman et al. 2003).   
On the basis of function, membrane transport proteins are divided to major superfamilies 
which are the ABC (ATP-binding cassette) transporters, and the SLC (solute carrier) 
transporters. While the human ABC transporter family comprises eight sub-families with 48 
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members, the SLC family has 47 subfamilies with more than 365 members (Leabman et al. 
2003). Genetic polymorphisms in drug transporters are considered to be the main factors 
affecting the variation of patients’ responses to medication (Kalliokoski and Niemi 2009). 
Most of the SLC family members act as influx transporters for nutrients and substances 
essential for the cell, whereas ABC members function as efflux transporters for wasted 
metabolites and toxins, including many anticancer drugs (Nakanishi and Tamai 2011). 
In humans, SLC transporters primarily are expressed in the liver, kidneys, lungs and 
intestines, but can be expressed in most tissues where they are either localized at the 
basolateral or apical plasma membranes of polarized cells (Wojtal et al. 2009). Furthermore, 
SLCs have two gene superfamilies which contain the major organic cation and anion 
transporters. The SLCO superfamily (previously called SLC21) consists of the organic anion 
transporting polypeptides (OATPs), while SLC22A that makes up the organic cation 
transporters (OCTs) and the organic anion transporters(OATs) (Roth et al. 2012).   
SLCs membrane-associated transporters mediate the main physiological functions by influx 
and efflux of endogenous substrates including amino acids, lipids and bile acids, thyroid 
hormones and xenobiotics (Hagenbuch and Meier 2004; Shitara and Sugiyama 2006; Meier 
et al. 2007). These transporters are the main focus of many pharmacokinetics studies as they 
play a significant role in drug absorption and are therefore important determinants of drug 
distribution(Meier et al. 2007; Le Vée et al. 2015). 
 
1.7. Drug metabolizing enzymes  
Most xenobiotic compounds including drugs, environmental pollutants and endogenous 
compounds such as steroids and prostaglandin are metabolized by a diverse group of proteins 
called drug metabolizing enzymes (DMEs)  (Sheweita 2000). Conceptually, DMEs can be 
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divided into two categories, the oxidative or phase I reactions, in which lipophilic substances 
are catalysed into more water soluble forms which are more easily excreted. These reactions 
can either lead to activation or inactivation of the compound. Phase I enzymes includes the 
cytochrome P450s (CYP), epoxide hydrolases(EH) and flavin mono-oxygenases (FMO) 
(Evans and Relling 1999; Pinto and Dolan 2011), while the conjugative or Phase II reactions 
increase the solubility of compounds, which is typically achieved by conjugation to a highly 
polar agent such as glucuronic acid. Phase II enzymes include thiopurine S-
methyltransferases (TPMT), uridine glucuronyl transferases (UGT), N-acetyltransferases 
(NAT), glutathione S-transferases (GST) and sulphonyl tansferases (SULT) (Sheweita 2000; 
Clouthier and Pelletier 2012). Most DMEs are polymorphic, appearing as small insertions 
and deletions, gene amplification and deletions, or as SNPs (Sim et al. 2013). Their presence 
can affect drug efficacy and toxicity (Serpe et al. 2014).  
 
1.8. Drug targets  
The total number of drug targets is currently limited for many reasons, including the inability 
to understand the existence of splice variants or interactions between the encoded proteins 
from gene sequences and the unknown function of most DNA in the genome (Imming et al. 
2006). Drug targets have been classified into enzymes, substrates, metabolites and proteins, 
receptors, ion channels, transport proteins, DNA / RNA and ribosome, and the targets of 
monoclonal antibodies. In addition, some  drugs act through physicochemical mechanisms, or 
have unrecognized mechanisms of action (Imming et al. 2006; Landry and Gies 2008). 
Genetic variability in drug targets  can have an unequivocal impact on drug efficacy, and that 
can be exemplified by sequence variations in the gene for the β2-adrenoreceptor which 
influences its response to β2-agonists and the reno-protective action of angiotensin-
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converting enzyme inhibitors are impacted by SNPs in the gene for angiotensin-converting 
enzymes (Wood et al. 2003). 
 
1.9. Pharmacogenetics profiling systems 
There are several techniques that have been developed for genotyping SNPs in recent years 
including: DNA Microarrays, MALDI-TOF spectrometry, FRET analysis, SNPlex, 
Pyrosequencing, TaqMan, High resolution melt technique (HRM) and Allele Specific 
Amplification (ASA) (De Monaco et al. 2014). 
  1.9.1. Allele specific PCR 
Allele specific PCR is also called PCR allele specific amplification (PASA), is a method used 
for the identification of single nucleotide polymorphisms by using allele specific primers  
(Papp et al. 2003). A recently developed technique called PCR amplification of multiple 
specific alleles (PAMSA) involves using at least two allele specific primers in the same 
reaction and allows for the detection of all SNPs present in one sample (Ishiguro et al. 2005; 
Hansson and Kawabe 2005).Many PAMSA methods allow for the discrimination of alleles 
by gel electrophoresis. Liu et al. (1997) described a variant of PAMSA called bidirectional-
PASA, in which one allele is amplified in one direction whereas the other allele is amplified 
in the opposite direction. However, for this method four primers are needed and accurate 
optimization of the target fragment can be time consuming and problematic (Liu et al. 1997; 
Sasvari‐Szekely et al. 2000; Waterfall and Cobb 2001, 2002).In PAMSA, a primer length 
difference of between 2 and 5 nucleotides is used, and alleles are resolved on acrylamide 
gels. This method may require the molar ratio of allele-specific primers to be optimized 
(Okimoto and Dodgson 1996). Gaudet et al. (2007) described that three unlabelled primers 
were necessary to amplify specific alleles. The alleles-specific primers that were used had a 
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destabilizing mismatch within five bases of the 3’ end and a 5’ tail for the amplification of 
different length PCR products, which were detected on an agarose gel (Gaudet et al. 2007).  
1.9.2 SNaPshot minisequencing (Single Base Extension reaction) 
There is an increasing focus on SNPs in the last few years. Traditionally, SNP analysis was 
performed with costly and time consuming techniques based on conventional PCR followed 
by restriction fragment analysis and gel electrophoresis (Quintáns et al. 2004).Recently, 
many high-throughput methods for studying SNPs have been developed including next 
generation sequencing (NGS), MALDI-TOF spectrometry, DNA Microarrays, FRET analysis 
and TaqMan assays or Molecular beacons (Quintáns et al. 2004). Despite the growing 
number of techniques, one method which is growing in popularity is the SNaPshot 
minisequencing assay which relies on a single base extension with a labelled ddNTP 
(Brandstätter et al. 2003). It is also less time-consuming and relatively rapid, while remaining 
robust and accurate compared to the traditional SNP analysis techniques like gel visualisation 
(Syvänen 1999). The commercialized multiplex SNaPshot system has been used increasingly 
in various genotyping studies, because it is highly accurate that can effectively detect many 
polymorphisms in a single assay (Paneto et al. 2011; Li et al. 2012).Technically, this method 
uses only fluorescently labelled dideoxynucleotide triphosphates (ddNTPs) to identify the 
allelic variant during the elongation of a primer  located beside the SNP of interest (Huang et 
al. 2011; Li et al. 2012). The chemical structure of ddNTPs (lacking a 2’ and 3’ hydroxyl 
group) prohibits any additional elongation, resulting in a product one nucleotide longer than 
the primer itself. This additional nucleotide can be visualized by a capillary automated 
sequencer. Each ddNTP is labelled with a specific fluorescent colour (fluorophore) for the 
different bases G,C,A,Ts which allows them to be identified (Rogers et al. 2012) and a fifth 
colour is used to label the internal size marker (Quintáns et al. 2004).  
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1.9.3. High resolution melt analysis  
High resolution melt (HRM) analysis is a closed-tube assay (i.e. less chance of cross-
contamination than other techniques), commonly used to detect mutations and 
polymorphisms in blindly screened DNA samples. The DNA is amplified by PCR with 
increasing temperature, in the presence of a saturating dye which only fluoresce in the 
presence of double stranded DNA followed by observing the progressive change in 
fluorescence during DNA denaturation in order to provide information about target DNA 
quantity (Ramón-Laca et al. 2014; Lim et al. 2015). The fluorescence data can be instantly 
analysed by using suitable software supplied by the manufacturer (Prajantasen et al. 2015). 
Basically, the HRM technique depends on the melting temperature of double stranded DNA, 
GC composition, sequence length and heterozygosity of the target (Reed et al. 2007; 
Baniecki et al. 2015). HRM analysis is rapidly becoming the favoured choice to detect 
pathogenic variants because it is simple, easy to use, cheap, flexible, non-destructive, 
sensitive and specific (Vossen et al. 2009; Vondráčková et al. 2015). Theoretically HRM is 
used to generate target amplicons less than 500bp, however due to its sensitivity and 
specificity, amplicons up to 1000 bp have been successfully amplified (Botezatu et al. 2015; 
Vondráčková et al. 2015). HRM has been successfully used to screen for mutations and 
genotyping of humans, animals, plants and microbes, as well as epigenetics and general 
population studies (Vondráčková et al. 2015). It is also a good method for individualized 
medicine  to predict drug response (Reed et al. 2007). 
 
1.10. Pharmacogenetics of anticancer drugs 
Variability in response and toxicity of anticancer drugs are consistently observed among 
patients which is a real problem in clinical practice that may lead to therapy failure or adverse 
drug reactions(Bosch et al. 2006; Huang and Ratain 2009). However, genetic variations in 
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drug metabolizing enzymes, transporters and targets genes have major effects on the 
observed differences in chemotherapeutic outcome. The aim of studying pharmacogenetics is 
to identify the genetic base for these differences and use it to predict optimal personalized 
drug regimes and dosage for the patient (Lee et al. 2005; Huang and Ratain 2009). There are 
two approaches used to evaluate how genetic variation contributes to differences in drug 
response and toxicity in humans(Huang and Ratain 2009). The first approach focuses on 
candidate genes which are involved in human pathophysiology, pharmacology, and cancer 
biology, based on the important role that genetic variations play in the pharmacokinetics or 
pharmacodynamics of a drug and the likelihood of  affecting its efficacy and/or toxicity 
(Huang and Ratain 2009). The second is genome-wide approach that refers to the study of 
genetic variations within the human genome for their impact on drug therapy, which any 
genetic variant in the  genome can contribute to variation in drug action (Huang and Ratain 
2009).  
Pharmacogenomic approaches have been applied to several anticancer drugs in an attempt to 
determine related inherited variations that are able to predict a patient’s response to cancer 
drugs (Lee et al. 2005). 
 
1.10.1. The Genetics of Cancer 
Cancer is a common genetic disease that originally develops from normal cells that are able 
to proliferate and become abnormal. These cells keep dividing to form more cells without 
normal cell cycle controls, forming a solid mass of excess tissue called a tumor which can be 
either malignant (cancerous) or benign (not cancerous) (Weinberg 2013). Tumor suppressor 
genes and oncogenes are two essential classes of genes that play a role in the carcinogenic 
process. The epigenetic changes could be inherited from parents or somatic (acquired) 
changes that are associated with environment or lifestyle (Hemminki and Hemminki 2005). 
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About 5 to 10% of all cancers are caused by inherited mutations, while 90 to 95 % are as a 
result of other environmental factors (Mgbakor et al. 2014). There is a noteworthy increase in 
cancer worldwide, specifically in less developed countries (Torre et al. 2015). It was 
estimated by the GLOBOCAN project (http://www.globocan.iarc.fr) that in 2008, 12.7 
million new cancer cases and 7.6 million cancer deaths occurred worldwide, with 56% of the 
new cancer cases and 64% of the cancer deaths occurring in the less developed countries  
around the world (Ferlay et al. 2010; Jemal et al. 2011). Similarly, Torre and co-workers 
estimated that of the14.1 million new cancer cases and 8.2 million deaths which occurred in 
2012, 57% of the new cases and 65% of deaths occurred in the less developed regions of the 
world (Torre et al. 2015).This increase can be attributed  to population growth, senility and 
harmful lifestyle (Jemal et al. 2011). 
In Africa, cancer is increasing at an alarming rate. In 2008, about 715,000 new cancer cases 
and 542,000 cancer deaths occurred on the continent (Cancer), whereas 847,000 new cancer 
cases (6% of  the whole world) and 591,000 deaths (7.2% of the whole world) were projected 
for 2012 (Parkin et al. 2014).As Africa has a wealth of extraordinary genetic diversity, it is 
thought to be an appropriate place to investigate cancer aetiology due to the impact of 
environmental factors on different genetic variations (Mgbakor et al. 2014). 
 
1.10.2. Cancer treatment and side effects 
Cancer treatment depends on the nature of the cancer and its progression. There are many 
types of cancer treatment including surgery, photodynamic therapy, chemotherapy, 
radiotherapy, immunotherapy, targeted therapy, hyperthermia, stem cell transplant, lasers, 
and blood product donation and transfusion (Thurston 2006) . 
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Chemotherapy refers to the use of medicines to treat cancer. Chemotherapeutic agents are 
classed according to the cellular phase in which they are active (S phase, M phase, G1 phase, 
G2 phase dependent) (Pazdur 2005). Nonspecific agents that do not target a specific cell 
cycle phase such as alkylating agents, show a linear dose-response curve, so further drug 
dosages increases cell killing, whereas cell cycle specific drugs have a plateau with regards to 
cell killing ability, so increases in drug dosage will not result in increased cells being killed 
(Page and Takimoto 2002) . 
Chemotherapy drugs can be divided into many classes which are: Alkylating agents such as 
cyclophosphamide which is activated in the liver (Lind 2011); platinum compounds such as 
cisplatin, carboplatin and oxaliplatin; and Antimetabolites which are subclassified into 
Antifolates (e.g.Methotrexate), Antipyrimidines (e.g. fluorouracil) and Antipurines 
(e.g.mercaptopurine and thioguanine) (Lind 2011). Although anticancer therapeutics are 
effective, current anticancer treatments have several drawbacks which ultimately affect their 
efficiency including that they are non-specific, and kill both normal and cancerous cells 
(Kawabe 2004). Some patients reported that they have experienced on average of 20 
symptoms during the treatment, of which 7 were psychosocial and 13 were physical (Griffin 
et al. 1996). The most common side effects reported were nausea, vomiting, sore mouth, 
tiredness, hair loss, difficulty sleeping, loss of taste, loss of appetite, passing more urine, dry 
skin and effects on their social lives (Griffin et al. 1996; Carelle et al. 2002). For most 
patients, vomiting is not as common or as acute as before due to improvements in antiemetic 
drugs. Nevertheless, vomiting is still a frequent symptom and in particular nausea remains a 
wide issue (Bloechl-Daum et al. 2006). Today, fatigue is other common side effect of 
anticancer drugs that affects about 80% of patients receiving chemotherapy (Henry et al. 
2008).    
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1.11. Pharmacogenomics of cholesterol lowering drugs 
The main factors that could impact the response of cholesterol lowering drugs (statins)  
include diseases, correlated with medications and adherence to treatment, biologic and 
physiologic conditions, and genetic background (Hutz and Fiegenbaum 2008). It has been 
suggested that genetic variations in influx and efflux transporters in the liver may modify the 
disposition of cholesterol lowering drugs. There are a considerable number of transporters 
that might have a role in statins transport, however relatively few have been analysed 
(Romaine et al. 2010). Few mutations have been reported that are medically related to SLCO 
genes. Several studies have focused on the impact of SLCO variants on drug disposition, 
taking in account pharmacokinetics of drugs (Hagenbuch and Stieger 2013). 
The Genetic diversity in the solute carrier organic anion transporter 1B1 (SLCO1B1) and 
solute carrier organic anion transporter 1B3 (SLCO1B3) genes varies greatly among 
continental populations which can help in pharmacogenetic studies conducted in mixed 
populations (Sortica et al. 2012).Such variations in these genes are responsible for the uptake 
of structurally different drugs and endogenous compounds from blood to the liver 
(Kalliokoski and Niemi 2009; Hagenbuch and Stieger 2013). A large number of variations 
have been discovered in SLCO1B1 which affect transport function (Niemi et al. 2011). The 
influence of SLCO1B1 polymorphisms on transport function leads to its substrate specificity 
(Tirona et al. 2001). Although clinical statins have been identified that are substrates of 
organic anion transporting polypeptide 1B1 (OATP1B1) (Furihata et al. 2009; Niemi 2010), 
many of statins are substrates of other hepatic organic anion transporting polypeptides 
(OATPs), such as pitavastatin which is a substrate of organic anion transporting polypeptide 
1B3 (OATP1B3) (Fujino et al. 2005). Recent studies have identified the altered 
pharmacokinetics of pravastatin and pitavastatin associated with polymorphisms in SLCO1B1 
(Smith et al. 2007). 
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1.11.1. Cholesterol  
 Cholesterol is a waxy, fatty substance that is an essential constituent in every cell in the body 
(Figure 1.1). Cholesterol has important biological functions, and is mainly produced in the 
liver and CNS. Cholesterol is naturally absorbed through the intestinal tract (Charlton-Menys 
and Durrington 2008). It is the major sterol component of the plasma membrane and 
organelle membranes, except for the mitochondrial membranes (Lange et al. 2004). The 
quantity of cholesterol in cells depends on the type of organelle and compartment. The 
endoplasmic reticulum (ER), where cholesterol is formed contains 0.1-2% of cholesterol in 
mole%, depending on cell type (Lange et al. 2004). Cholesterol is very important for many 
biological processes; including the formation of lipids in cell membranes, as well as being a 
precursor for the synthesis of vitamin D, steroid hormones and bile acids (Brookes et al. 
2009). Changes in cholesterol levels can have deep influences on membrane transport 
(Charlton-Menys and Durrington 2008). Synthesized cholesterol is carried by two types of 
lipoproteins that are produced by the liver and intestine. High density lipoproteins (HDL) 
carry cholesterol from cells to the liver, where it is broken down as a waste product. 
Conversely, low density lipoproteins (LDL) carry cholesterol from the liver to body cells. 
Excess cholesterol can accumulate in the walls of arteries and lead to atherosclerosis (Gylling 
2004). Most cholesterol is synthesized in the body, while cholesterol gained from food is a 
minor component (Ikonen 2006).     
 
Figure1.1- Chemical structure of cholesterol 
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1.11.2. Lipoproteins 
Lipids are insoluble in plasma and therefore need to be transported as complexes with 
proteins, these complexes are called lipoproteins (Lusis and Pajukanta 2008). Lipoproteins 
are spherical particles (Figure 1.2 A), whose major constituents can include non-polar lipids 
of cholesterol esters and triglycerides, as well as polar components including free cholesterol, 
phospholipids and proteins (Shen et al. 1977).  
 
 
Figure 1.2 A-Structure of lipoproteins 
Figure 1.2 B-Relationship of lipoproteins components to diameter and density (Ridker 2014). 
 
 
Lipoproteins are categorized into classes with different ratios of fat and protein which lead to 
differences in density and size of the complexes (Figure 1.2 B). The classes are: very low 
density lipoproteins (VLDL), low density lipoproteins(LDL), intermediate density 
lipoproteins(IDL) and high density lipoproteins(HDL), as well as chylomicrons (Zhang et al. 
2011). 
 
1.11.3. Familial hypercholesterolemia 
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Familial hypercholesterolemia (FH) is an inherited autosomal (not related to the sex 
chromosomes) co-dominant genetic disorder. FH is mainly caused (85–90% of the cases) by 
mutations in the LDL receptor gene (LDLR), while 5–10% of the cases are linked to 
mutations in apolipoprotein B (APOB). Approximately 1% of the cases are the result of 
mutations in proprotein convertase subtilisin/kexin type 9 gene (PCSK9) (Davidson et al. 
2011; Gouni-Berthold and Berthold 2015). FH is characterized by very high LDL cholesterol, 
tendon xanthomas and premature cardiovascular disease (Chiou and Charng 2012). 
FH has been classified into two forms, heterozygous (heFH)form in which the patient inherits 
FH gene from one parent (Kwiterovich et al. 1974). HeFH is a relatively common disease 
with an estimated prevalence of 1/500 in most populations (Durrington 2001; Chiou and 
Charng 2012). However, the rare homozygous (hoFH) form occurs when the patient inherits 
the FH gene from both parents (Raal and Santos 2012). Globally the prevalence of hoFH is  
estimated to be 1 case in 1million people (Raal and Santos 2012) .  
HeFH is more frequent in specific populations, which is shown 1/100 among Afrikaners, 
1/170 among Christian Lebanese, 1/270 among French Canadians (Izar et al. 2010) and 1/208 
in the Hokuriku district of Japan (Mabuchi et al. 2011; Raal and Santos 2012). However, 
prevalence hoFH in these groups is estimated to be 1/30000, 1/100000, 1/275000 and 
1/171167, respectively (Raal and Santos 2012).  
1.11.4. Cholesterol lowering drugs 
Hydroxy methylglutaryl coenzyme A (HMG-CoA) Reductase Inhibitors (also called statins) 
are a type of drugs that reduce low-density lipoprotein cholesterol levels (Cho et al. 2015). 
Structurally statins are analogues of 3-hydroxy-3-methylglutaryl coenzyme A reductase 
(HMG-CoA) (Figure1.3) and strongly inhibit hepatic conversion of HMG-CoA reductase, 
thereby limiting cholesterol biosynthesis (Endres 2005; Pahan 2006). 
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There are five types of statins available as a medication that approved by US Food and Drug 
Administration (FDA), including lovastatin, simvastatin, pravastatin, fluvastatin and  
atorvastatin (Manzoni and Rollini 2002). Current  studies show that due to their multiple 
functions, statins could be used for pharmaceutical treatment of several disorders including 
cancer, diabetes, inflammation, neurodegeneration and demyelination (Pahan 2006). In spite 
of the effectiveness of statins in lowering cholesterol levels in the blood, they have some side 
effects that cannot be disregarded, such as the fact that they cause myopathy, severe liver 
problems (Brookes et al. 2009), and an increased risk of  hemorrhagic strokes (Goldstein et 
al. 2008). Statins play a role in the development of heart disease and atherosclerosis because 
cholesterol plays in a main role in synthesising lipids and hormones in the body, therefore 
statins do not decrease cholesterol production only, but might affect other products synthesis 
(Brookes et al. 2009). 
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Figure 1.3-Structure of HMG-CoA and different types of statins (Shitara and Sugiyama 
2006). 
 
1.12. Genetic polymorphisms of drug metabolizing enzymes, transporters and targets 
It has well known that genetic variability in genes encoding drug metabolizing enzymes, 
transporters and targets comprises the main causes of inter-individual differences in 
therapeutic outcome (Evans 2004; Serpe et al. 2014).  
The following enzymes, transporters and targets harbouring well determined polymorphisms 
with clinical effect on FDA anticancer efficacy, and specific transporters with clinical effect 
on FDA cholesterol lowering drugs efficacy, were chosen for this study. 
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1.12. 1.Genetic variations associated with FDA approved anticancer drugs   
1.12.1.1. Catechol O-mthyltransferase enzyme: 
Catechol O-methyltransferaseenzyme (COMT) is encoded by the COMT gene which is an 
important gene involved in cisplatin cancer drug metabolism and is linked with ototoxicity in 
children (Fung et al. 2011). Ototoxicity is a serious problem that affects about 60% of 
patients receiving cisplatin (Ross et al. 2009). The genetic variations rs9332377 and 
rs4646316 in the COMT gene have been identified and are associated with hearing damage in 
children who receiving cisplatin (Ross et al. 2009).  
1.12.1.2. Dihydropyrimidine dehydrogenase enzyme: 
Dihydropyrimidine dehydrogenase enzyme (DPYD) is the first and rate-limiting factor in 
pyrimidines catabolism (Seck et al. 2005; Largillier et al. 2006; Saif 2013). It has been 
proposed that DPYD deficiency is associated with toxicities to the cancer drug fluorouracil 
(Li et al. 2014), and genetic polymorphisms in DPYD gene were responsible for DPYD 
deficiency (Luo et al. 2015). The SNPs rs2297595 and rs3918290 in the DPYD gene are 
linked to a decreased efficacy of fluorouracil and also cause severe toxicity (Gentile et al. 
2015). Patients with DPYD mutations may have severe drug-adverse effects following 
fluoropyrimidines (capecitabine and fluorouracil) therapy (Gross et al. 2008). The variant 
rs3918290 is associated with severe toxicity to capecitabine (Deenen et al. 2011), and the 
SNP 2297595 was found to be associated with toxicity, particularly in patients with breast 
and gastroesophageal cancer (Gross et al. 2008). 
1.12.1.3. Thiopurine S-methyltransferase enzyme: 
Thiopurine S-methyltransferase (TPMT) is an enzyme that catalyses the S-methylation of 
thiopurines such as azathioprine, thioguanine, and mercaptopurine (Spire‐Vayron de la 
Moureyre et al. 1998; Zeglam et al. 2015). Patients with inherited deficiency in TPMT 
activity treated with standard doses of thiopurine cancer drugs are at an elevated risk of 
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thiopurine toxicity (Weinshilboum 2001). The three SNPs in the TPMT gene, rs1142345, 
rs1800460 and rs1800462have been reported as the most common mutant alleles linked with 
the loss of TPMT activity in many populations (Murugesan et al. 2010) and with the 
incidence of adverse effects to thiopurines (Gazouli et al. 2010). 
 TPMT also plays a significant role in cisplatin metabolism and correlated with ototoxicity in 
paediatric patients (Fung et al. 2011). The SNPs rs1142345 and rs1800460 are associated 
with hearing loss in children treated with cisplatin (Ross et al. 2009).   
1.12.1.4. Transmembrane Protein 43: 
Transmembrane Protein 43 (TMEM43) is a 43 kDa putative membrane protein whose 
structure and function are undetermined (Siragam et al. 2014). This transporter is encoded by 
the TMEM43 gene (van der Zwaag et al. 2009). The SNP rs2228001 in the TMEM43 gene 
might decrease the activity of the transporter, and patients with the rare allele who receive 
cisplatin may be at higher risk of ototoxicity (Caronia et al. 2009).   
1.12.1.5. Methylene- tetrahydrofolate reductase enzyme:   
Methylene-tetrahydrofolatereductase (MTHFR) is an important enzyme that regulates folate 
metabolism (Shen et al. 2001) and is encoded by the MTHFR gene (Kałużna et al. 2015). 
Polymorphisms in MTHFR and the variant genotypes lead to decreased MTHFR enzyme 
activity and lower plasma folate level (Shen et al. 2001). Studies have shown that the 
common SNP rs1801133 is associated with a decreased activity of the enzyme MTHFR 
(Cortese and Motti 2001). In addition, this variant significantly increased the toxicity of 
methotrexate when used with carboplatin as a treatment for ovarian cancer (Toffoli et al. 
2003; Kim 2009). Severe acute toxicity could occur in patients with the AA genotype after 
the first cycle of adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) 
chemotherapy (Toffoli et al. 2000b). 
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1.12.1.6. Glutathione S-transferase P enzyme: 
For the purpose of cell protection, GSTs enzymes catalyze the conjugation of glutathione to 
xenobiotics to form glutathione disulfide (Hayes and McLellan 1999; Geng et al. 2014). The 
genetic variant of GSTP1 gene (rs1695) has been indicated to be relevant to the response of 
anthracycline-based chemotherapy (e.g. epirubicin) in breast cancer (Tulsyan et al. 2013). 
The variant G is correlated with increased risk of toxicity in colorectal cancer patients (Braun 
et al. 2009) and increased risk of neutropenia in lupus erythematosus patients treated with 
cyclophosphamide (Zhong et al. 2006). However, in women with breast cancer, this SNP was 
not associated with adverse drug reactions after cyclotophosphamide containing 
chemotherapy (Ekhart et al. 2008; Low et al. 2009).   
 
1.12.2. Genetic polymorphisms associated with FDA approved cholesterol lowering 
drugs: 
1.12.2.1. Solute carrier organic anion trasporter1B1 (SLCO1B1) gene: 
It was identified that all types of statins that are used clinically are substrates of the 
transporter OATP1B1 (gene name SLCO1B1) (Niemi et al. 2011).Numerous variants have 
been found within the SLCO1B1gene (Romaine et al. 2010). The common SNPs rs4149056 
and rs2306283 are associated with decreased the hepatic transporter OATP1B1 activity 
(Niemi et al. 2011).   
The SNP rs11045819 genotype CC has been shown to exhibit significantly less LDL 
reduction and higher post-treatment LDL levels (Couvert et al. 2008). It has been identified 
that the SNPs rs4149015 and rs4149056 were linked with reduced plasma concentrations of 
pravastatin on paediatric patients with HeFH and cardiac transplant recipients treating with 
immunosuppressive drugs (Hedman et al. 2006). The SNP rs4149036 is associated with 
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triglyceride lowering, but only among those homozygous for the rare allele (Thompson et al. 
2005). 
1.12.2.2. Solute carrier organic anion trasporter1B3 (SLCO1B3) gene 
Statins are among the drugs that are substrates of OATP1B3 (gene name SLCO1B3) (Kindla 
et al. 2011). OATP1B3 is an important hepatic transporter that shares several substrates with 
OATP1B1, such as rosuvastatin and pravastatin (Ho et al. 2006; Seithel et al. 2007; Niemi et 
al. 2011). It was identified that the SNP rs72559743 reduces protein expression and activity 
of the protein, contrasted with SNP rs4149117 that increases the activity in vitro (Letschert et 
al. 2004). The SNP 60140950 has a harmful effect on the function of the protein (Geraldine 
et al.). It was reported that the SNP rs12299012 reduces the uptake of rosuvastatin (Schwarz 
et al. 2011). To date there is no clinical data available for SNP rs57585902. 
 
1.13. Statistical Analyses 
1.13.1 GenAlEx 
Genetic Analysis in Excel (GenAlEx) is an in-MS-Excel application used for population 
genetic analysis. GeneAlEx can be used to calculate allele frequency, the Hard-Weinberg 
Equilibrium and the Shannon and Fixation indices (Peakall and Smouse 2012). 
1.13.2. The Hardy-Weinberg Equilibrium 
The Hardy-Weinberg equilibrium (HWE) hypothesises that allele and genotype frequencies 
in a population remain constant or they are in equilibrium from generation to generation, 
unless other external influences are presented (Hardy 2003). These influences include: 
mutation, selection, population size, mating, gene migration and random genetic drift. 
However, this means static allele frequencies of HW which assumes no mutation, no 
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migration, no selection, random mating (no inbreeding) and a large population (no genetic 
drift) do not exist in nature (Butler 2005). However, the HWE is still an ideal state used to 
determine genotype frequencies. 
1.14. The aims of the study: 
This study aims to develop and evaluate the performance of robust and high throughput 
techniques for genotyping ten polymorphisms related to anticancer drugs and ten 
polymorphisms related to cholesterol lowering drugs. These assays will be developed using a 
SNaPshot minisequencing panel which is considered to be an accurate, less time-consuming 
and relatively rapid method for detection many polymorphisms in a single assay, as well as 
high resolution melt analysis as an alternative, fast and cheap typing method. In addition, 
HRM assays will be evaluated and the results validated by comparing them to those obtained 
by SNaPshot assays (the gold standard assay for genotyping). Lastly, both assays will be 
validated using direct sequencing. 
 In addition, the minor allele frequencies of ten previously identified SNPs 
pharmacogenetically associated with FDA approved anticancer drugs, and the minor allele 
frequencies of ten previously identified SNPs pharmacogenetically associated with FDA 
cholesterol lowering drugs will be determined. Allele and genotype frequencies for the 
investigated SNPs will be compared to different population groups from around the world. 
 
 
 
 
 
 
 
 27 
 
Chapter Two 
Development of a pharmacogenomic profiling panel for anticancer drugs 
2.1. Introduction  
Cancer in Africa is a serious health issue compounded by communicable diseases (e.g. HIV), 
changes in life style and age (Parkin et al. 2008). It has been noticed that the differences in 
cancer drug responses and toxicity is a serious problem amongst patients which might lead to 
treatment failure or adverse drug reactions (Bosch et al. 2006; Huang and Ratain 2009). 
However, it has been shown that the genetic polymorphisms in drug metabolizing enzymes, 
transporters and targets genes may explain the differences of chemotherapeutic outcome. 
There are several chemotherapeutics that are used for cancer treatment. Despite their 
effectiveness, many exhibit serious side effects (Kawabe 2004). The importance of studying 
genetic variations has been introduced in the case of chemotherapeutics such as Azathioprine 
and mercaptopurine with variant alleles in the TPMT gene has been shown to put patients at 
risk for toxicity. This has helped physicians develop personalised dose regimes (Wilke et al. 
2007). Cisplatin is a widely used and highly effective anticancer agent. Nevertheless, 
ototoxicity can affect about 60% of patients who are receiving this treatment (Ross et al. 
2009).  It was reported that the SNPs rs9332377 and rs4646316 in the COMT gene and the 
SNPs rs1142345 and rs1800460 in the TPMT gene, are linked to ototoxicity in children 
receiving cisplatin (Ross et al. 2009). Hence, pharmacogenetics studies aim to identify these 
genetic variations and use them as a baseline to predict the optimal chemotherapy dose for 
each patient (Lee et al. 2005; Huang and Ratain 2009). 
Africa has a wealth of genetic diversity, so it is considered to be a good place to study how 
environmental factors influence the different genetic variations in relation to cancer treatment 
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(Mgbakor et al. 2014). South Africa is a multi-ethnic country and susceptibility to different 
types of cancer vary between ethnic groups (Bezwoda et al. 1997). It is home to different 
groups that include Khoisan, Xhosa, Zulu, Venda, and Sotho Pedi, the Afrikaners and the 
Cape Admixed the latter being a uniquely admixed population of immigrant Europeans, 
Asians and indigenous populations (Hardy et al. 2008; Du Plessis et al. 2015). The 
complexity in Admix populations in particular creates advantages for studying the clinical, 
environmental, and genetic ancestry of population differences in health outcomes (Suarez-
Kurtz 2008a; Via et al. 2009). Therefore, the objectives of this part of the project was to 
develop a SNaPshot minisequencing system to investigate the genotypic and allelic profile of 
ten previously reported single nucleotide polymorphisms relevant to anticancer drugs in 130 
South African Cape Admixed individuals living in Cape Town. The SNaPshot methodology 
is high throughput and fast, as it is based on single base extension with a labelled ddNTP (Hu 
et al. 2016). The minor allele frequencies (MAF) of the Cape admixed population were 
compared to several other populations. Ethnic populations that were included in this study 
were: British in England and Scotland (GBR) which represent European Caucasian, 
Colombian in Medellin, Colombia (CLM) and Mexican ancestry in Los Angeles, California 
(MXL) both represent Latino admixed population, Gujarati Indian in Houston, Texas (GIH) 
represent Asian, African ancestry in South-western US represent African American (ASW), 
Luhya in Webuya, Kenya (LWK) and Yoruba in Ibadan, Nigeria (YRI) both represent sub-
Saharan African populations. The SNPs were selected from various population groups as per 
Ensembl(http://www.Ensembl.org/Homo_sapiens/Variation/Population?db=core;r=22:19967
669-19968669;v=rs9332377;vdb=variation;vf=4986831). 
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2.2. Materials and Methods 
2.2.1. Sample Collection 
Biological samples were obtained in the form of buccal swabs from 130 apparently healthy, 
unrelated volunteers from the Cape Admixed population living in Cape Town, South Africa. 
Ethnicity of volunteers was determined by self-report. To confirm the volunteers’ mixed 
ancestry, the questionnaires included a short genealogy of two generations for maternal and 
paternal family members, as well as place of birth, home language and religious affiliation. 
Ethical approval for this project was obtained from the Senate Research Committee of the 
University of the Western Cape with a registration no: 10/9/40. 
2.2.2. DNA Extraction  
Genomic DNA was extracted using a standard salt lysis method. The cotton tip of each swab 
was cut off with a clean scalpel surgical blade. The excised pieces of the swab were added to 
a sterile 1.5ml Eppendorf tube containing 600 µl of salt lysis buffer (0.4 M NaCl, 0.01 M 
Tris-HCl (pH 8), 2 mM EDTA, 1% SDS) and 3µl of 20mg.ml
-1
 Proteinase K. The tubes were 
shaken vigorously and incubated shaking overnight at 60°C at 115 rpm in a G24 
Environmental Incubator shaker (New Brünswick Scientific Co., Inc., USA). After which the 
entire volume was transferred to a sterile tube. The lysis solution containing the biological 
material in the swab was recovered by using spin columns. The end of a 0.5 ml tube was 
perforated with a sterile surgical needle and placed inside a clean 1.5 ml Eppendorf tube and 
centrifuged at 14000 rpm for 1 min in an Eppendorf centrifuge 5417 (Eppendorf, Germany). 
The collected volume was added to the separated lysis material.  To precipitate the DNA, 
200 µl of 6M NaCl was added and the tubes were shaken vigorously for 15 sec and 
centrifuged at 5000 rpm for 15min. The supernatant containing the DNA was transferred to 
another sterile tube. A volume of 600 µl isopropanol was added and the tubes were incubated 
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at -80°C for 30 min. The DNA was collected by centrifugation at 14000 rpm for 30 min then 
washed with 100 µl of 70% Ethanol and centrifuged at 14 000 rpm for 10 min to remove 
excess salts. The pellets were air dried and re-suspended in a final volume of 50 µl of 1x TE 
buffer (1M Tris and 0.5M EDTA, pH 7). Samples were stored at -20°C. The concentration of 
DNA was measured by using a Nanodrop ND 1000 UV-Vis Spectrophotometer (Thermo 
Fisher Scientific, Inc., USA).  
2.2.3. SNP Selection 
A total of ten SNPs, seven non-synonymous and three intronic, were targeted for this part of 
this project. SNP selection was based on the available evidence on clinical relevance of 
genetic variants in anticancer therapy as gathered from the Pharmacogenomics 
Knowledgebase (http://www.pharmgkb.org), US Food and Drug Administration website 
(FDA) (http://www.FDA.gov) and Ensembl database (http://www.Ensembl.org). Genetic 
variants were initially selected based on the FDA's table of pharmacogenomic biomarkers in 
drug labelling for cancer therapy, and narrowed down to ten SNPs using additional clinical 
relevance data available in the Pharmacogenomics Knowledgebase 
(http://www.pharmgkb.org) (Table 2.1). 
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                   Table2.1- A list of genes and selected SNPs associated with anticancer therapy: 
 
 
 
 
 
 
 
 
 
 
 
 
 Ref: Pharmacogenomics Knowledgebase (http://www.pharmgkb.org), US Food and Drug Administration website (FDA) (http://www.FDA.gov).
SNP ID Gene  Type of gene Drug Clinical observation 
rs9332377 COMT Drug metabolizing enzyme Cisplatin
 
Ototoxicity 
rs3918290 DPYD Drug metabolizing enzyme Capecitabine, Fluorouracil and Tegafur
 
Drug toxicity 
 rs2297595  DPYD Drug metabolizing enzyme Capecitabine and Fluorouracil
 
Drug toxicity 
rs2228001 TMEM43 Drug  transporter Cisplatin
 
Ototoxicity and toxicity 
rs1142345 TPMT Drug metabolizing enzyme Cisplatin 
Thioguanine
 
Ototoxicity 
Drug toxicity 
rs1800460 TPMT Drug metabolizing enzyme Cisplatin 
Thioguanine
 
Ototoxicity 
Drug toxicity 
rs4646316 COMT Drug metabolizing enzyme Cisplatin
 
Ototoxicity 
rs1801133  MTHFR Drug  target Cyclophosphamide, Methotrexate and Carboplatin                               Drug toxicity 
rs1800462 TPMT Drug metabolizing enzyme Azathioprine , Thioguanine and purine analogous Drug toxicity 
rs1695 GSTP Drug metabolizing enzyme Cyclophosphamide, Epirubicin and Platinum compounds
 
Drug toxicity 
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2.2.4. Primer Design 
Primers were designed to genotype the selected SNPs in one multiplex PCR. The primers, 
which are listed in Table 2.2, were designed to have an annealing temperature between 55°C 
and 60°C using Primer3plus software (http://primer3plus.com/cgi-bin/dev/primer3plus.cgi) 
and Ensembl database (http://www.Ensembl.org). Primers were aligned on Ensembl using 
BLAST (http://www.ensembl.org/Multi/Tools/Blast) to test for nonspecific amplification. 
Multiplex SNaPshot minisequencing primers listed in Table 2.3, in which poly (gcat) tails 
were added at the 5’ end of the specific hybridizing part of the primer to generate a range of 
different sized primers.  The final sizes ranged between 30 to 75 bp. Both PCR and SNaPshot 
minisequencing primers were synthesised by Inqaba Biotec, South Africa. 
 
 
 
 
 33 
 
          Table2.2- Multiplex PCR primers for the selected SNPs related to anticancer drugs used in SNaPshot™ genotyping. 
Gene 
NCBI 
(dbSNP) 
Forward primer (5´to 3´) Reverse Primer (5ʹto 3ʹ) 
Amplicon length 
 (bp) 
COMT rs9332377 GTCTCCAGGGACCATACCAG GCTGGGTGAGTGGAAACAAT 107 
DPYD rs3918290 TGGACAAAGCTCCTTTCTGA TCACCAACTTATGCCAATTCTC 149 
DPYD rs2297595 CCAGCACCAAAAAGAGCAAT AAAACAAGAATTCGTTTGAAACAT 194 
TMEM43 rs2228001 GCCTCAAAACCGAGAAGATG CTGCCTCAGTTTGCCTTCTC 237 
TPMT rs1142345 GGGGAATTGACTGTCTTTTTGA TTGCAATCTGCAAGACACAT 316 
TPMT rs1800460 CCCTGATACCTGAGCCAGAG TTACCATTTGCGATCACCTG 375 
COMT rs4646316 ACGCTTCTCTTGGAGGTGAG TCTGCAGGAGACACATGCTT 431 
MTHFR rs1801133 AGGACAGTGTGGGAGTTTGG CTCACCTGGATGGGAAAGAT 470 
TPMT rs1800462 TCTGCTTTCCTGCATGTTCTT CAGGAATTTCGGTGATTGGT 265 
GSTP           rs1695 GCTGGGGCTCACAGACAG GTGCAGGTTGTGTCTTGTCC 381 
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2.2.5. PCR Amplification 
 PCR amplification was performed using the KAPA2G Fast Multiplex PCR mix (KAPA 
BIOSYSTEMS, South Africa) in a final volume of 25 µl according to manufacturer’s 
instructions. Each reaction contained a minimum of 20 ng genomic DNA. PCR 
amplifications were performed in a GeneAmp 2700/ 2720 (Applied Biosystems, USA) 
thermal cycler. PCR cycling conditions were carried out as follows: initial denaturation at 
95°C for 3 min, denaturation at 95°C for 15 sec, annealing at 60°C for 15 sec, elongation at 
72°C for 15 sec, for a total of 30 cycles, followed by final extension at 72°C for 1 min and a 
hold step at 4°C. PCR products were confirmed by agarose gel electrophoresis on 2% gels 
and visualised under UV light. 
2.2.6. Post PCR Purification 
The PCR products were purified to remove excess primers and unincorporated ddNTPs using 
a Thermosensitive Alkaline Phosphatase (FastAP) (Thermoscientific, U.S.A) and 
Exonuclease I (Exo1) (Thermoscientific, U.S.A). PCR products were incubated with 0.5 μl of 
Exo1 and 1 μl of FastAP at 37°C for 15 min followed by thermal deactivation of the enzymes 
at 75°C for 15 min in a GeneAmp 2700/ 2720 (Applied Biosystems, USA) thermal cycler. 
2.2.7. SNaPshot minisequencing (Single Base Extension) 
The reaction was performed using the SNaPshot® kit according to the manufacturer’s 
specifications (Applied Biosystems, U.S.A). The final 10 μl reaction volume contained 3 μl 
of the purified PCR products, 0.2 μΜ of primers (final concentration), 2 μl of SNaPshot® 
ready mix and 3μl water. Negative and positive controls for the mini-sequencing reactions 
were prepared according to manufacturer’s instructions. A GeneAmp 2700 thermal cycler 
(Applied Biosystems, USA) was used for the minisequencing reactions. Sequencing cycling 
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conditions consisted of 25 cycles of denaturation at 96°C for 10 sec, annealing at 50°C for 5 
sec, and extension at 60°C for 30 sec, followed by a holding step at 4°C.  
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Table 2.3- SNaPshot minisequencing reaction primers of the selected SNPs related to anticancer drugs. 
NCBI 
(dbSNP) 
Amino Acid 
Change 
Nucleotide 
Change 
Minisequencing Reaction Primers  Primer Direction 
Position 
Accession number 
(NC_000006.12) 
Size bp Poly GCAT tail 
rs9332377 Intron C>T AGTATCCGGACTCAAGGACCGTGACCCACA Reverse 19968169 30 0 
rs3918290 Intron C>T ACTGAACTAAAGGCTGACTTTCCAGACAAC Reverse 97450058 35 5 
rs2297595 M166V T>C ACGAAACTTATGGATGCCCCTTTAGTTGGC Reverse 97699535 40 10 
rs2228001 G939L G>T GCAGCAGCTTCCCACCTGTTCCCATTTGAG Reverse 14145949 45 15 
rs1142345 T240C T>C AGATGAATGTCTTTTCATTTACTCTGTATC Forward 18130687 50 20 
rs1800460 A154T C>T GGCAAATTTGACATGATTTGGGATAGAGGA Reverse 18138997 55 25 
rs4646316 Intron C>T CACACCCCAGACCAGACACCAGGGCAGAAA Forward 19964609 60 30 
rs1801133 A222V G>A AGCACTTGAAGGAGAAGGTGTCTGCGGGAG Reverse 11796321 65 35 
rs1800462 A80P C>G AAGTGTAAATGTATGATTTTATGCAGGTTT Reverse 18143724 70 40 
rs1695 L105V A>G GACGGCGTGGAGGACCTCCGCTGCAAATAC Forward 67585218 75 45 
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2.2.8. Post Extension Purification 
Post Extension products were purified by adding 1 U of FastAP to the 10 µl reaction volume 
and incubated at 37°C for 30 minutes followed by 15 minutes at 75°C to inactivate the 
enzyme in a GeneAmp 2700 thermal cycler (Applied Biosystems, USA). 
2.2.9. Electrophoresis of the minisequencing products 
Reactions were set up in a 96-well plate in POP4 polymer (Applied Biosystems, USA). To 
each well, 8.7 μl HiDi Formamide (Applied Biosystems, USA) and 0.3 μl GeneScan Liz 120 
size standard (Applied Biosystems, USA) were mixed with 1μl of the purified 
minisequencing product. The plate was briefly centrifuged for 1 min at 1000 rpm and 
incubated in a thermal cycler for DNA denaturation at 95°C for 5 min. Subsequently, the 
fluorescently labelled fragments were separated on 36 cm-long capillary containing POP4 
polymer on ABI Prism 3500 DNA sequencer (Applied Biosystems, USA). Data was analysed 
using GeneMapper® IDX Software Version 1.4 (Applied Biosystems, USA).  
2.2.10. Statistical Analysis 
The statistical analysis of Genotype and allele frequencies, as well as the deviation from the 
Hardy-Weinberg Equilibrium were calculated using GenAlEx 6.5 software (Peakall and 
Smouse 2012). Allele and genotype frequencies are given with binomial proportion 95% 
confidence intervals (CI). The Chi-square test was used to determine if individual variants 
were in Hardy-Weinberg Equilibrium (HWE) at each locus. 
2.3. Results: 
The sample group enrolled in this study consisted of 130 healthy individuals from the Cape 
Admixed Population; 12 (9%) females and 118 (91%) males between the ages of 14 and 68 
years. Minor optimization was needed for the primer sets of the two SNPs (rs1801133 and 
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rs1800462). Due to poor amplification, the concentration of these two primers pairs was 
increased to 0.4 µM in the PCR amplification. Also minor optimization was required for 
these two SNPs in SNaPshot minisequencing reaction, in which the concentration was also 
increased to 0.4 µM. This resulted in good profiles for each. In certain cases the fragments 
migrated further than its indicated size which is likely due to minisequencing chemistry 
(Quintáns et al. 2004). Genotypes were confirmed with direct sequencing as described in 
Chapter 4. Electropherogram profile of the SNaPshot minisequencing genotyping system is 
displayed in Figure 2.1. 
 
 
Figure 2.1- Electropherogram profile of the SNPs related to anticancer drugs. Green peaks indicate an A 
nucleotide, blue peaks indicate a G nucleotide, black peaks indicate a C nucleotide and red peaks indicate a T 
nucleotide. 
The allelic frequency of each SNP was determined to be in HWE (P>0.05), with the 
exception of SNPs rs1801133 and rs3918290. The expected and observed genotype 
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frequencies in the study are determined under the Hardy-Weinberg Equilibrium. The 
genotype and allele frequencies of the ten selected SNPs relevant to anticancer drugs 
observed in Cape Admixed Population are summarized in Table 2.4. The minor allele 
frequency for the ten variants was compared globally to seven ethnic groups, which were: 
BGR (British in England and Scotland), CLM (Colombian in Medellin, Colombia), MXL 
(Mexican ancestry in Los Angeles in California), GIH (Gujarati Indian in Houston), ASW 
(African ancestry in Southwest US), LWK (Luhya in Webuye, Kenya) and YRI (Yoruba in 
Ibadan, Nigeria). The comparison was summarized in Table 2.5 and depicted in Figure 2.2. In 
our study, rs3918290 was the only investigated SNP found to be monomorphic. The 
heterozygosity was observed in two intronic and seven nonsynonomous SNPs. The intronic 
variant rs9332377 genotype frequencies for wild-type (CC), heterozygote (CT) and 
homozygote (TT) were 74.6%, 24.6% and 0.8%, respectively. Furthermore, the intronic 
variant rs4646316 genotype frequencies showed homozygote 57.7% for the wild-type (CC), 
38.5% for heterozygote (CT) and 3.8% for homozygote (TT). The M166V (rs2297595) 
genotype frequencies for wild-type (TT), heterozygote (TC), and homozygote (CC) were 
91.5%, 8.5% and 0.0%, respectively. The G939L (rs2228001) genotype frequencies for wild-
type (TT), heterozygote (TG), and homozygote (GG) were 46.9%, 47.7% and 5.4%, 
respectively. T240C (rs1142345) genotype frequencies for wild-type (TT), heterozygote 
(TC), and homozygote (CC) were 94.6%, 5.4% and 0.0%, respectively. The A154T 
(rs1800460) genotype frequencies for wild-type (CC), heterozygote (CT), and homozygote 
(TT) were 97.7%, 2.3% and 0.0%, respectively. The A222V (rs1801133) genotype 
frequencies for wild-type (GG), heterozygote (GA), and homozygote (AA) were 48.5%, 13% 
and 38.5%, respectively. A80P (rs1800462) genotype frequencies for wild-type (CC), 
heterozygote (CG), and homozygote (GG) were 99.2%, 0.8% and 0.0%, respectively. L105V 
 
 
 
 
 40 
 
(rs1695) genotype frequencies for wild-type (GG), heterozygote (GA), and homozygote (AA) 
were 12.3%, 50% and 37.7%, respectively. 
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Table 2.4 - Genotype and allele frequencies of selected SNPs related to anticancer drugs in 130 
healthy Cape Admixed individuals. 
Amino Acid 
Substitution 
 
 
Gene 
 
 
dbSNP ID 
 
Observed Genotype Frequency 
 
Allele Frequency 
Genotype % 95% CI Allele % 95% CI 
HWE 
(P) 
 Intron 
 
rs9332377 
CC 74.6  67.12 – 82.08 C 86.9  82.8 - 91  
0.345  
 
COMT CT  24.6 17.2 – 32 T  13.1 9 - 17.2 
TT  0.8 0.0 -2.33    
          
Intron 
 
rs3918290 
CC 100.0  100-100  C 100.0  100-100  
NA DPYD CT 0.0   0.0 T 0.0  0.0  
TT 0.0  0.0    
          
M166V 
 
rs2297595 
TT 91.5  86.71-96.29 T  95.8  93.36- 98.24 
0.614 DPYD TC  8.5 3.71 -13.29  C 4.2 1.76- 6.64 
CC  0.0 0.0    
          
G939L 
 
rs2228001 
TT 46.9  38.32- 55.48 T 70.8  65.27-76.33 
0.082 TMEM43 TG  47.7 39.11- 56.29 G  29.2 23.67-34.73 
GG  5.4 1.51- 9.29    
          
T240C 
 
rs1142345 
TT  94.6 90.71- 98.49 T 97.3  95.33- 99.27 
0.752 TPMT TC  5.4 1.51- 9.29 C  2.7 0.73- 4.67 
CC  0.0 0.0    
          
A154T 
 
rs1800460 
CC  97.7 95.12- 100 C 98.8  97.48-100 
0.894 TPMT CT  2.3 0.0-4.88 T  1.2 0.0-2.52 
TT  0.0 0.0    
          
Intron 
 
rs4646316 
CC 57.7  49.21- 66.19 C 76.9  71.78-82.02 
0.342 COMT CT  38.5 30.14- 46.86 T  23.1 17.98-28.22 
TT  3.8 0.51- 7.09    
          
A222V 
 
MTHFR rs1801133 
GG 48.5  39.91- 57.09 G  55 48.95-61.05 
0.000 
GA  13 7.22- 18.78 A  45 38.95-51.05 
AA  38.5 30.14- 46.86     
          
A80P 
 
rs1800462 
CC 99.2  97.67-100 C 99.6  98.83-100 
0.965 TPMT CG  0.8 0.0-2.33 G  0.4 0.0 -1.17 
GG  0.0 0.0    
          
L105V 
 
rs1695 
GG 12.3  6.65-17.95 G 37.3  31.42-43.18 
0.432 GSTP GA  50 41.41- 58.59 A  62.7 56.82-68.58 
AA  37.7 29.37- 46.03    
P-Value will be NA for monomorphic SNPs (MAF =0). 
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Table 2.5 - Comparison of MAF of the selected SNPs related to anticancer drugs in the Cape Admixed population to other ethnic groups. 
 
a. This study, b. Data from Ensembl database (http://www.Ensembl.org).
dbSNP ID 
Amino acid 
change 
Minor 
Allele 
Minor Allele Frequency (%) 
Cape 
Admixed
 a  British 
b 
Colombian
 b
 Mexican 
b
 Indian 
b African 
American
 b
 
Luhya
b
 Yuroba
b
 
rs9332377 Intron T 13.1 15.9 14.9 8.6 21.4 33.6 33.3 35.2 
rs3918290 Intron T 0.0 0.0 0.0 0.0 1.5 0.8 0.0 0.0 
 
rs2297595 
 
M166V 
 
C 
 
4.2 
 
8.2 
 
6.4 
 
7.0 
 
3.4 
 
4.9 
 
10.1 
 
0.9 
 
rs2228001 
 
G939L 
 
G 
 
29.2 
 
38.5 
 
29.3 
 
25.8 
 
34 
 
33.6 
 
27.3 
 
26.9 
 
rs1142345 
 
T240C 
 
C 
 
2.7 
 
3.3 
 
2.1 
 
4.7 
 
2.4 
 
9.8 
 
11.6 
 
6.0 
 
rs1800460 
 
A154T 
 
T 
 
1.2 
 
2.7 
 
1.1 
 
3.9 
 
0.0 
 
2.5 
 
0.0 
 
0.0 
 
rs4646316 
 
Intron 
 
T 
 
23.1 
 
20.3 
 
21.8 
 
16.4 
 
9.2 
 
23.8 
 
16.7 
 
16.2 
 
rs1801133 
 
A222V 
 
A 
 
45.0 
 
32.4 
 
54.3 
 
46.9 
 
15 
 
13.9 
 
7.1 
 
10.6 
 
rs1800462 
 
A80P 
 
G 
 
0.4 
 
1.1 
 
1.1 
 
0.0 
 
0.0 
 
0.8 
 
0.0 
 
0.0 
 
rs1695 
 
L105V 
 
A 
 
62.7 
 
68.1 
 
64.4 
 
43.8 
 
68.9 
 
54.1 
 
49.0 
 
60.2 
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Figure2.2- Allele frequencies of the selected SNPs related to anticancer drugs in the Cape Admixed population compared to other ethnic groups. 
 
Cape Admixed (This study); British, Colombian, Mexican, Indian, African American, Luhya and Yuroba (Ensembl database).
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2.4. Discussion: 
The SNaPshot minisequencing assay is one of the most efficient, rapid and accurate 
ways for high throughput genotyping that requires little optimization steps (Quintáns 
et al. 2004). In this part of the project, SNaPshot minisequencing method was 
successfully used and optimized to investigate 10 SNPs relevant to anticancer drugs 
within 130 unrelated healthy individuals of the Cape Admixed population in South 
Africa. Cancer is increasing globally, especially in less developed countries (Torre et 
al. 2015). It is estimated that approximately 5-10% of all cancers are caused by 
inherited mutations (Mgbakor et al. 2014). It is well known that chemotherapeutics 
effectiveness is associated with ethnic differences which have profound effects on the 
response and toxicity to these agents (Chen et al. 2010). Differences in patients drug 
metabolizing enzymes, transporters and targets genes are considered to be the major 
source on the variability in treatment outcome (Evans 2004; Serpe et al. 2014).  
The Cape Admixed population has high genetic diversity compared to the indigenous 
populations. This unique population has contributed to inter-individual genetic 
variability, which may account for the observed physiological differences, especially 
with respect to drug uptake and metabolism. From the results presented it can be seen 
that the Cape Admixed population shares many genetic variations with other ethnic 
groups.  
The intronic variants rs9332377 and rs4646316 in the COMT gene which encodes for 
the enzyme catechol-O-methyltransferase, have previously been shown to be linked to 
an increased risk of hearing damage in a study on 162 paediatric cancer patients 
receiving cisplatin (Ross et al. 2009). However, a recent study by Yang et al. (2013) 
on 213 children with medulloblastoma and 41 with solid tumors showed no relation 
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between hearing damage and these variants. In our population, the MAF observed for 
the intronic SNPs in COMT gene was 13.1% for rs9332377, which was a bit lower 
than Colombian (14.9%) and higher than Mexican populations (8.6%), and 23.1% for 
rs4646316 which was slightly higher than Colombian (21.8%), Indian (21.4%) and 
British (20.3%) populations.  
The intronic variant rs3918290 and M166V (rs2297595), were detected in the DPYD 
gene which encodes the enzyme dihydropyrimidine dehydrogenase. These variants 
were reported by Gentile et al. (2015) to be responsible for decreasing efficacy of 
fluorouracil and cause acute toxicity. However, the incidence of severe toxicity was 
observed in SNP rs3918290 in patients who underwent treatment with 
fluoropyrimidines, such as fluorouracil and capecetabine, but no clear association 
with the M166V (rs2297595) variant and sever toxicity was found (Toffoli et al. 
2015). Deenen et al. (2011) enrolled advanced colorectal cancer Dutch patients in a 
study which described that the DPYD variants rs3918290 and rs2297595 lead to 
severe toxicity with capecitabine-based chemotherapy. Furthermore, rs3918290 was 
also confirmed as a cause of severe toxicity to tegafur as fluorouracil prodrugs 
(Terrazzino et al. 2013). It was suggested by some studies that patient’s gender could 
affect the toxicity of fluorouracil. Many studies have showed women are more prone 
to fluorouracil toxicity than men (Schwab et al. 2008). However, it was described by 
another study that the correlation of the variant rs3918290 with fluorouracil toxicity 
was significantly higher in men than in women (Schwab et al. 2008; Caudle et al. 
2013). The intronic DPYD gene SNP rs3918290 was not observed in the Cape 
admixed, British, Hispanic (Mexican and Colombian) and sub-Saharan populations. 
However, it was observed in African Americans with a MAF of 0.8% and Indians 
with a MAF of 1.5%. The substitution M166V (rs2297595) was observed with a MAF 
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of 4.2% which was a bit lower than the observed frequency for African Americans 
(MAF of 4.9%) and slightly higher than Indians that reported a MAF of 3.4%. 
In the TMEM43 gene which encodes for the transmembrane protein 43 (van der 
Zwaag et al. 2009), the SNP rs2228001 with the amino acid substitution G939L was 
previously shown to increase the risk of cisplatin- induced hearing loss (Caronia et al. 
2009). Caronia et al. investigated 91 osteosarcoma patients receiving cisplatin, and 
found that only 32 patients had ototoxicity in which patients with GG genotype were 
more prone to have ototoxicity than patients with the GA and AA genotypes. 
Moreover, this variant has been predicted to cause severe toxicity in a study 
consisting of 101 patients with bladder cancer treated with platinum-based 
chemotherapy (Sakano et al. 2010). In our population, this variant showed a MAF 
with 29.2% that was similar to Colombian population (29.3%). However, the MAF 
was higher than those of Mexican and sub-Saharan African populations (Table2.5). 
The variants T240C (rs1142345) and A154T (rs1800460) in the TPMT gene, which 
encodes for thiopurine methyltransferase, were found to increase the risk of hearing 
loss in child cancer patients treated with cisplatin (Ross et al. 2009). Conversely, a 
study by Yang et al. observed no relationship between these variants and hearing loss 
in children taking cisplatin. Moreover, he found no functional differences in TPMT 
knockout against wild-type mice after treatment with cisplatin (Yang et al. 2013). It 
has been identified that patients with inherited low levels of TPMT enzyme activity 
are at a higher risk for toxicity when treated with thiopurines, such as thioguanine , 
azathioprine, and mercatopurine (Murugesan et al. 2010). Moreover, it was 
determined that the TPMT polymorphisms (T240C, A154T and A80P), were the most 
common mutant alleles correlated with loss of TPMT enzyme activity in many 
populations (Murugesan et al. 2010). Furthermore, in previous studies on children 
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with inflammatory bowel disease (IBD) treated with thiopurines, these 
polymorphisms did not show a significant correlation with adverse effects to these 
drugs (Stocco et al. 2005; Ridder et al. 2006; Gazouli et al. 2010). The MAF for the 
variant T240C was 2.7% in our population, which was quite similar to Indians (2.4%). 
However, it is slightly higher than Colombians (2.1%) and lower than the British 
population (3.3%). While, the MAF for the variant A154T was 1.2%, which is similar 
to Colombian (1.1%) and lower than British, Mexican and African Americans (Table 
2.5). Further, the MAF for the variant A80P was 0.4% which was lower than British 
(1.1%), Colombian (1.1%) and African American (0.8%). However, it was 
significantly high compared to Mexican, Indian and sub-Saharan populations which 
all had a MAF of 0.0%. 
In the MTHFR gene encodes for methylene-tetrahydrofolate reductase (Kałużna et al. 
2015), the substitution A222V (ra1801133) has been shown to reduce enzyme activity 
and affect chemosensitivity of cancer cells (Martin et al. 2006). Ulrich and co-
workers investigated  220 chronic myelogenous leukemia patients, and they showed 
that in patients with the AA genotype, MTHFR activity appeared to be decreased and 
they are at a higher risk of methotrexate toxicity (Ulrich et al. 2001). In another study 
on Caucasian ovarian cancer patients treated with methotrexate only or combined with 
carboplatin, showed that AA genotype was associated with methotrexate-induced 
hyperhomocysteinaemia and patients were at a higher risk of treatment related toxicity 
(Toffoli et al. 2003). Moreover, this SNP has also been observed to reduce 
chemosensitivity to methotrexate in breast cancer cell lines (Sohn et al. 2004). Toffoli 
and co-workers also found a higher incidence of acute toxicity in Caucasian breast 
cancer patients carrying the AA genotype during CMF (cyclophosphamide, 
methotrexate, and fluorouracil) treatment (Toffoli et al. 2000a). Furthermore, in a 
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study consisting of 248 women with breast cancer, African American and Caucasian 
women with the GA and AA genotypes for A222V (ra1801133) were shown to have 
an increased cancer survival rate (Martin et al. 2006). However, in another study, no 
relationship between this variation and disease-free survival was found in breast 
cancer patients treated with FEC (cyclophosphamide, epirubicin, and fluorouracil) or 
CMF (Pare et al. 2007). The variant A222V (rs1801133) was detected in our studied 
population with a MAF of 45% which was lower than the Mexican population 
(46.9%), however, it was clearly higher than African Americans, Indians, Luhya and 
Yoruba that showed a MAF of 13.9%, 15%, 7.1% and 10.6%, respectively. 
The SNP rs1695 in the GSTP gene, that encodes for glutathione S-transferase, results 
in the amino acid change L105V, was observed in 94 women with breast cancer 
receiving anthracycline based CEF (cyclophosphamide, epirubicin, and fluorouracil) 
treatment. The study found that GG genotypes were associated with homological 
toxicity (Zárate et al. 2007). However, a study on Chinese patients with breast cancer, 
has shown that patients with the G allele have increased survival following 
cyclophosphamide-based chemotherapy than those with the A allele (Ge et al. 2013). 
In another study, colorectal cancer patients were found to be at an increased risk of 
toxicity when treated with cyclophosphamide (Braun et al. 2009). Moreover,  patients 
with AA genotype had increased oxaliplatin-induced neuropathy (Lecomte et al. 
2006). The MAF for L105V variant was 62.7% in our population which was lower 
than the Colombians (64.4%), Indians (68.9%) and British population (68.1), but 
higher than Mexican, African American and sub-Saharan populations (Table2.5).  
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 2.5. Conclusion 
Pharmacogenetics gives a unique way for studying and investigating the variability in 
response of chemotherapeutic drugs which have a narrow curative effect and show 
inter-individual differences. However, understanding the impact of genetic variations 
in drug metabolizing enzymes, transporters and targets could provide a solution to 
precision cancer treatment based on a patient’s genetic profile, ensuring they receive 
the drug with the highest efficacy and lowest toxicity. This study investigated the 
allele and genotype frequencies of ten SNPs in six pharmacogeneticaly cancer 
relevant genes in the South African Cape Admixed population. SNaPshot method was 
used successfully for high throughput genotyping. The genotypic and allelic 
frequencies obtained were compared globally to different ethnic groups. 
Ultimately, the genotype and allele frequency data of this study could assist in 
providing effective cancer treatments in the correct dosages for the South African 
Cape Admixed population. 
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Chapter Three 
Development of a Pharmacogenomic profiling panel of cholesterol lowering drugs 
3.1. Introduction 
Many transporters play an essential role in the membrane transport of clinical drugs, as they 
are involved in absorption, distribution and excretion of drugs (Tamai 2012). In addition, the 
ability of transporters to change the tissue concentrations of drugs such as statins, affects 
their pharmacological and/or toxicological properties (Giacomini et al. 2010; Shitara et 
al. 2013). However, it has been recognized that genetic variations play a role in determining 
a patient’s drug response and susceptibility to toxicity to statins (Needham and Mastaglia 
2014).  
The genetic structure in the organic anion-transporting polypeptide 1B1 (OATP1B1) and the 
organic anion-transporting polypeptide 1B3 (OATP1B3) varies from one population to 
another around the world which creates a great chance for pharmacogenetic studies (Sortica 
et al. 2012). The solute carrier organic anion transporter family member 1B1 (SLCO1B1) 
gene and the solute carrier organic anion transporter family member 1B3 (SLCO1B3) gene 
that code for OATP1B1 and OATP1B3, respectively are thought to mediate the influx and 
metabolism of statins in the liver (Schwarz et al. 2011). Some studies have previously shown 
connections between genetic variations in SLCO genes and the pharmacokinetics of substrate 
uptake. For example, the common variation V174A (rs4149056) in the SLCO1B1 reduces the 
activity of the OATP1B1 transporter which leads to increase plasma concentrations of several 
statins (Niemi et al. 2011). 
In this part of this study, we developed a robust genotyping system based on the SNaPshot 
minisequencing reaction to investigate the genotypic and allelic distributions of five SNPs in 
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the solute carrier organic anion transporter 1B1 (SLCO1B1) gene and five SNPs in the solute 
carrier organic anion transporter 1B3 (SLCO1B3) gene related to cholesterol lowering drugs. 
In addition, we generated important pharmacogenomic data for FDA approved cholesterol 
lowering drugs. The data was compared to different ethnic groups worldwide. The haplotype 
structure of these genes was designated and possible implications of the genetic variations on 
cholesterol lowering drugs in the South African Cape Admixed population are discussed. 
3.2. Materials and Methods 
3.2.1. Sample Collection 
Samples collection was as described in Chapter Two. 
3.2.2. DNA Extraction 
Genomic DNA was extracted from buccal swab samples using a standard salt-lysis method 
and stored at -20°C as described in Chapter Two. 
 
3.2.3. SNP Selection 
Ten single nucleotide polymorphisms (SNPs) were investigated in this part of the study. 
SNPs were selected based on the available evidence on clinical relevant genetic variants in 
cholesterol lowering therapy as gathered from the Pharmacogenomics Knowledgebase 
(http://www.pharmgkb.org), US Food and Drug Administration website (FDA) 
(http://www.FDA.gov), the UCSF-PMT (http://www.pharmacogenetics.ucsf.edu/) database 
and Ensembl database (http://www.Ensembl.org ). Genetic variants were initially selected 
based on the FDA's table of pharmacogenomic biomarkers in drug labelling for cholesterol 
lowering drugs, and narrowed down to ten SNPs using additional clinical relevance available 
in the Pharmacogenomics Knowledgebase (http://www.pharmgkb.org). 
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3.2.4. Primer Design 
All primers were designed as described in Chapter two. PCR primers were designed to have 
an annealing temperature between 52°C and 55°C. Table 3.1 shows a list of PCR primers and 
Table 3.2 shows minisequencing primers.  
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Table 3.1- Multiplex PCR primers for the selected SNPs related to Cholesterol lowering drugs used in SNaPshot™ genotyping. 
Gene 
NCBI 
(dbSNP) 
Forward primer (5´to 3´) Reverse Primer (5ʹto 3ʹ) 
Amplicon length 
 (bp) 
SLCO1B1 rs4149056 CATGGCTTTGCTCTTCCTTC TGTAAGAAAGCCCCAATGGT 404 
SLCO1B1 rs2306283 GGGGAAGATAATGGTGCAAA GCTGCCTGTGTGTTCTCAAA 561 
SLCO1B1 rs4149015 TGGCCTTGGGTCTACATTTC CGTGGTATGTATGGAGACTGGA 661 
SLCO1B1 rs11045819 CAACATCGACCTTATCCACTTG TGTTAATGGGCGAACTGTGT 249 
SLCO1B1 rs4149036 CCTCTGTGCCACTATCAGTACC      GCTTCAGTGAAATGATGGGAAC 348 
SLCO1B3 rs4149117 CATTTGGGGCATTCAGTTCT TCTCAAAAGGTAACTGCCCACT 307 
SLCO1B3 rs57585902 ACCCACTTTGTTCATGGTGT GGTGGTGGGTTTCTCCTTCT 594 
SLCO1B3 rs60140950 GCACACAAGATCAGGCAATG CCTTGGTTGGTCAAATTAGC 465 
SLCO1B3 rs12299012 GGGTGAATGCCCAAGAGATA CCCCTCACATCCCCTTACTT 888 
SLCO1B3 rs72559743 ACACTGCCTGCCTGATCTCT TGTGGTACCTCCTGTTGCAG 764 
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3.2.5. PCR Amplification:  
The PCR reactions were performed as described in Chapter two. Cycling parameters were 
carried out as follows: initial denaturation at 95°C for 3 min, a total of 30 cycles of 
denaturation at 95°C for 15 s, annealing at 55°C for 15 sec, extension at 72°C for 15 sec, 
followed by final extension at 72°C for 1 min and a hold step at 4°C.  
3.2.6. Post PCR purification: 
PCR products were purified as described in Chapter Two. 
3.2.7. SNaPshot minisequencing reaction (Single base extension): 
Minisequencing reaction was performed in a 10 µl reaction volume using 3 µl of the purified 
PCR products, 0.4 µM of primers, and 2 µl of SNaPshot™ ready reaction mix (Applied 
Biosystems, U.S.A). Sequence cycling was performed according to the manufacturer’s 
instructions.  
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Table 3.2-SNaPshot minisequencing reaction primers of the selected SNPs related to cholesterol lowering drugs. 
NCBI 
(dbSNP) 
Amino Acid 
Change 
Nucleotide 
Change 
Minisequencing Reaction Primers 
 
 
 
Primer 
Direction 
 
Position 
Accession number 
(NC_000006.12) 
Size bp Poly GCAT tail 
rs4149056 V174A T>C GGAATCTGGGTCATACATGTGGATATATG Forward 21178615 30 0 
rs2306283 N130D G>A AGTTACAGGTATTCTAAAGAAACTAATATC Forward 21176804 35 5 
rs4149015 Intron G>A CATTTTCACACATATATACATATGTACATA              Reverse 21130388 40 10 
rs11045819 P155T C>A GACTCTATCACCCTTTTCCATTCTTAATTA            Reverse 21176879 45 15 
rs4149036 Intron C>A TTATTATTATCCCTTTAAATAGGCAGTTAC Forward 21174806 50 20 
rs4149117 S112A G>T CTCCTTATGGGAACTGGAAGTATTTTGAC        Forward 20858546 55 25 
rs57585902 T147A A>G GGAATAGTAAGTTACCTTGTAGTGGACTC              Reverse 20861096 60 30 
rs60140950 G256A G>C GAATAACTCCTAAGGACTCTCGTTGGGTTG        Forward 20875274 65 35 
rs12299012 V560A T>C CAGGAGGTACCACATTTATCTTGTTGACTG                      Forward 20883599 70 40 
rs72559743 G522C G>T CACTTACGGGTTCTCTATTATGAACATGTT          Reverse 20883484 75 45 
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3.2.8. Post Extension Purification 
Post-extension products were purified as described in Chapter Two. 
3.2.9. Electrophoresis of the minisequencing products 
The fluorescently labelled fragments were separated on an ABI Prism 3500 Genetic Analyzer 
(Applied Biosystems, USA) as described in Chapter Two. Data was analyzed using 
GeneMapper® IDX Software Version 1.4 (Applied Biosystems, USA). 
3.2.10. Statistical Analysis 
The statistical analysis of the data was done using the freely available software, GenAlEx as 
described in Chapter Two, as well as  the SHEsis analysis platform was used to deduce the 
haplotype frequencies (Yong and Lin 2005; Li et al. 2009). 
 
3.3. Results: 
3.3.1. SNaPshot minisequencing Genotyping: 
Our studied population composed of a 130 healthy, unrelated Cape Admixed participants 
residing in Cape Town, South Africa. There were 12 (9%) females and 118 (91%) males 
between the ages of 14 and 68 years. 
In this chapter, a SNaPshot multiplex assay was developed for genotyping five SNPs in 
SLCO1B1 and five SNPs in SLCO1B3 transporters genes in intronic and coding regions that 
are associated with FDA cholesterol lowering drugs (statins). The original primer 
concentration for the amplification reactions was 0.2 µM. However, minor optimization of the 
SNaPshot minisequencing reaction was required and the primer concentration was increased 
to 0.4µM for all the SNPs to get better results for each. As described in Chapter Two a 
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notable number of shifts for fragments during capillary electrophoresis were detected. 
Genotypes were confirmed with direct sequencing is discussed in detail in Chapter Four. A 
typical electropherogram profile of the SNaPshot minisequencing genotyping system of the 
ten selected SNPs relevant to cholesterol lowering drugs is displayed in Figure 3.1. 
 
Figure 3.1- Electropherogram profile of the SNPs related to cholesterol lowering drugs. Green peaks indicate an 
A nucleotide, blue peaks indicate a G nucleotide, black peaks indicate a C nucleotide and red peaks indicate a T 
nucleotide. 
SNaPshot genotyping results in the Cape Admixed are reported in Table 3.3. The minor allele 
frequency (MAF) for the ten variants was compared to seven different ethnic groups which 
were: BGR (British in England and Scotland), CLM (Colombian in Medellin, Colombia), 
MXL (Mexican ancestry in Los Angeles in California), GIH (Gujarati Indian in Houston), 
ASW (African ancestry in Southwest US), LWK (Luhya in Webuye, Kenya) and YRI 
(Yoruba in Ibadan, Nigeria), summarized in Table 3.4 and depicted in Figure 3.2. 
Only two SNPs (rs4149056 and rs2306283) were determined to be in HWE (p>0.05). Four 
out of the ten studied SNPs were monomorphic in the Cape Admixed population. None of the 
participants were homozygous for the variant allele for N130D (rs2306283), P155T 
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(rs11045819), G256A (rs60140950), S112A (rs4149117), V174A (rs4149056) and the 
intronic (rs4149036). The N130D variant genotype frequencies for wild-type homozygote 
(GG), heterozygote (GA) and mutant homozygote (AA) were 50.8%, 36.2% and 13%, 
respectively (Table 3.3). The P155T variant genotype frequencies for wild-type homozygote 
(CC), heterozygote (CA) and mutant homozygote (AA) were 61.5%, 38.5% and 0.0%, 
respectively. The genotype frequencies for G256A variant wild-type homozygote (GG), 
heterozygote (GC) and mutant homozygote (CC) were 96.1%, 3.1% and 0.8%, respectively. 
Interestingly, while this variant was not observed in African American and Yoruba; it was 
observed in the Cape Admixed, British, Colombian and Mexican populations (Table 3.4). 
The S112A variant genotype frequencies for wild-type homozygote (GG), heterozygote (GT) 
and mutant homozygote (TT) were 63.1%, 36.9% and 0.0%, respectively. The intronic 
variant rs4149036 genotype frequencies for the wild-type homozygote (CC), heterozygote 
(CA) and mutant homozygote (AA) were 48.5%, 50% and 1.5%, respectively. The variant 
V174A genotype frequency for wild-type homozygote (CC) was 90.8%, while heterozygote 
(CT) and mutant homozygote (TT) were 8.4 % and 0.8%, respectively. The intronic variant 
rs4149015 was not observed in the Cape Admixed and Yoruba. However, it was observed in 
the other populations. Two variants, T147A (rs57585902) and V560A (rs12299012) were not 
observed in the Cape Admixed, British, Colombian and Mexican; however, they were 
observed in the African American and the sub-Saharan populations. No population data was 
found for the variant G522C (rs72559743) on the database, which was not observed in the 
Cape Admixed population. 
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Table 3.3 - Genotype and allele frequencies of the selected SNPs related to cholesterol 
lowering drugs in 130 healthy Cape Admixed individuals. 
Amino Acid 
Substitution 
 
 
Gene 
 
 
dbSNP ID 
 
Observed Genotype Frequency 
 
Allele Frequency 
Genotype % 95% CI Allele % 95% CI 
HWE 
(P) 
 V174A 
 
rs4149056 
TT 90.8 85.83-95.77 T 95 92.35- 97.65  
0.213  
 
SLCO1B1 TC  8.4 3.63-13.17 C 5 2.35-7.65 
CC  0.8 0.0-2.33    
          
N130D 
 
rs2306283 
GG 50.8 42.21-59.39 G 68.8 63.17- 74.43 
0.073 SLCO1B1 GA 36.2 27.94- 44.46 A 31.2 25.57- 36.83 
AA 13 7.22- 18.78    
          
Intron 
 
rs4149015 
GG 100.0 100-100 G 100.0 100-100  
NA SLCO1B1 GA 0.0 0.0 A 0.0  0.0 
AA 0.0 0.0    
          
P155T 
 
rs11045819 
CC 61.5 53.14-69.86 C 80.8 76.01- 85.59 
0.007 SLCO1B1 CA 38.5 30.14-46.86 A 19.2 14.41-23.99 
AA 0.0 0.0    
          
Intron 
 
rs4149036 
CC 48.5 39.91-57.09 C 73.5 68.14-78.86 
0.001 SLCO1B1 CA 50 41.41-58.59 A 26.5 21.14- 31.86 
AA 1.5 0.0-3.59    
          
S112A 
 
rs4149117 
GG 63.1 54.81-71.39 G 81.5 76.78- 86.22 
0.010 SLCO1B3 GT 36.9 28.61-45.19 T 18.5 13.78- 23.22 
TT 0.0 0.0    
          
 T147A 
 
rs57585902 
AA 100.0 100-100 A 100.0 100-100  
NA SLCO1B3 AG 0.0 0.0 G 0.0 0.0  
GG 0.0 0.0    
          
G256A 
 
rs60140950 
GG 96.1 92.77-99.43 G 97.7 95.88-99.52 
0.000 SLCO1B3 GC 3.1 0.12-6.08 C 2.3 0.48-4.12 
CC 0.8 0.0-2.33    
          
V560A 
 
rs12299012 
TT 100.0 100-100 T 100.0 100-100  
NA SLCO1B3 TC 0.0 0.0 C 0.0   0.0 
CC 0.0 0.0    
          
       NA G522C 
 
rs72559743 
GG 100.0 100-100 G 100.0 100-100  
SLCO1B3 GT 0.0 0.0 T 0.0   0.0 
TT 0.0 0.0    
P-Value will be NA for monomorphic SNPs (MAF =0). 
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      Table 3.4- Comparison of MAF of the SNPs related to cholesterol lowering drugs of the Cape Admixed population to other ethnic groups. 
 
     a.This study, b. Data from Ensembl database (http://www.Ensembl.org) 
dbSNP ID 
Amino acid 
change 
Minor 
Allele 
Minor Allele Frequency (%) 
 Cape 
admixed 
a British 
b 
Colombian 
b 
Mexican 
b 
Indian 
b African-
American 
b Luhya 
b 
Yoruba 
b 
rs4149056 V174A C 5.0 14.3 18.1 7.8 1.9 6.6 2.0 0.9 
rs2306283 N130D A 31.2 64.3 52.1 62.5 44.7 25.4 15.7 18.5 
rs4149015 Intron A 0.0 2.2 6.9 2.3 5.8 0.8 3.0 0.0 
rs11045819 P155T A 19.2 15.4 14.9 5.5 2.9 6.6 2.5 5.1 
rs4149036 Intron A 26.5 18.1 25.0 12.5 10.7 54.9 56.6 59.7 
rs4149117 S112A T 18.5 13.2 11.2 13.3 6.8 51.6 72.2 65.3 
rs57585902 T147A G 0.0 0.0 0.0 0.0 0.0 4.1 2.5 5.6 
rs60140950 G256A C 2.3 15.9 14.9 4.7 9.2 0.0 0.5 0.0 
rs12299012 V560A C 0.0 0.0 0.0 0.0 0.0 0.8 2.0 2.8 
rs72559743 G522C T 0.0 ND ND ND ND ND ND ND 
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Figure 3.2- Allele frequencies of the selected SNPs related to cholesterol lowering drugs compared to other ethnic groups. 
Cape Admixed (This study); British, Colombian, Mexican, Indian, African American, Luhya and Yuroba (Ensembl database). 
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3.3.2. Haplotype analysis: 
Haplotypes were calculated using the SHesis online platform. Twelve haplotypes were 
distinguished from the five SNPs in the SLCO1B1gene, and four haplotypes were identified 
from the five SNPs in the SLCO1B3 gene (Table 3.5A and Table 3.5 B). The most frequently 
observed haplotypes in the SLCO1B1gene were T G G C C (33.2%), T A G C C (28.3%), T 
G G C A (14.7), T G G A A (9.4%) and T G G A C (7.8%), while the most frequently 
observed haplotypes in SLCO1B3gene were G A G T G (79.2%) and T A G T G (18.5%). 
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Table3.5 A- Haplotype structure defined by the 5 SNPs in the SLCO1B1 gene in the Cape 
Admixed population. 
 
Haplotype No. Haplotypes 
(1)
 Frequency % 
Haplotype *1 T G G C C 33.2 
Haplotype *2 T A G C C 28.3 
Haplotype *3 T G G C A 14.7 
Haplotype *4 T G G A A 9.4 
Haplotype *5 T G G A C 7.8 
Haplotype *6 C G G C A 1.7 
Haplotype *7 T A G A C 1.6 
Haplotype *8 C G G C C 1.5 
Haplotype *9 C A G C A 0.7 
Haplotype *10 C A G C C 0.6 
Haplotype *11 C G G A C 0.5 
Haplotype *12 T A G C A 0.0 
  Total 100  
 
Table3.5 B-Haplotype structure defined by the 5 SNPs in the SLCO1B3 gene in the Cape 
Admixed population. 
Haplotype No. Haplotypes 
(1)
 Frequency % 
 Haplotype*1 
 
G A G T G 
 
 79.2 
Haplotype*2  
 
T A G T G 
 
 18.5 
Haplotype*3 
 
G A C T G 
 
2.3  
Haplotype*4 
 
T A C T G 
 
0.0 
  Total 100  
1 - Haplotype sequences are based on the position of SNPs on chromosome 12. 
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3.4. Discussion: 
The SNaPshot minisequencing reaction was selected as it is an easy, accurate, and high 
throughput method for SNP analysis. Minimal optimization of increasing the primer 
concentration to 0.4 µM for each SNP was required to get good profiles. As a part of the 
project, ten SNPs in SLCO1B1 and SLCO1B3 genes were genotyped in 130 unrelated healthy 
individuals of the Cape Admixed population in South Africa.  
Drug transporters are important proteins involved in drug absorption, tissue accumulation and 
elimination from the body. Thus, recent interest has focussed on the contribution of inter-
individual variability that affect drug transporter function in drug response (DeGorter 2012). 
OATPs transporters encoded by the SLCO genes are uptake transporters with wide substrate 
specificity although statins are considered to be their commonly specified substrates. 
Furthermore, hepatocytes are the major site of stains action where transporter proteins from 
OATP1B subfamily are expressed (DeGorter 2012; Romaine et al. 2010). 
The common variant V174A (rs4149056) was found to be associated with altering the 
transporter activity of pravastatin in vitro (Tirona et al. 2001). Moreover, different studies 
have confirmed that this substitution is linked to decreased hepatic transporter activity of 
rosuvastatin, atorvastatin and pravastatin (Tirona et al. 2003; Katz et al. 2006;Oswald et al. 
2008). Thompson et al. studied the variant V174A (rs4149056), and noticed a significant 
effect on the ability of fluvastatin to affect HDL cholesterol (Thompson et al. 2005). 
However, they did not notice any significant associations for LDL cholesterol lowering. 
Furthermore, a study enrolled elderly patients with vascular risk or at risk of vascular disease 
showed that the V174A variant showed less pravastatin induced low LDL-Cholesterol levels 
(Akao et al. 2012). A previous study identified that the V174A  was correlated with reduced 
plasma concentrations of pravastatin in paediatric heterozygous familial 
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hypercholesterolemia (HeFH) (Hedman et al. 2006). The MAF for V174A recorded by 
Rajput et al. in study conducted on Pakistani population was observed at 23.9% (Rajput et al. 
2014). However, in the present study the variant was observed to have a MAF of 5% in the 
Admixed population which was lower than Mexican and African American, but higher than 
sub-Saharan and Indian populations (Table 3.4). 
It was reported that the variant N130D (rs2306283) was responsible for OATP expression in 
the liver cells (Nies et al. 2013). In a study, it  has been found that N130D associated with a 
significant increase in atorvastatin response, which was an evaluated reduction in LDL-
cholesterol (Rodrigues et al. 2011). Also, Kadam and co-workers identified in their recent 
study of 177 hypercholesterolaemic Indian patients undergoing atorvastatin treatment, that 
the variant N130D displayed a notable reduction of LDL-cholesterol in response to 
atorvastatin (Kadam et al. 2016). This variation was observed in our population with a MAF 
of 31.2% which was significantly lower than the Hispanic, Indian and British populations.  
Hedman et al. (2006) reported that the intronic SNP rs4149015 was associated with reduced 
plasma concentrations of pravastatin in children with heterozygous familial 
hypercholesterolemia (HeFH). This variant was not observed in Cape Admixed or in the 
Yoruba. However, it was recorded in British, Hispanic, Indian and African American 
populations (Table 3.4).  
In a study of 420 French patients with hypercholesterolemia used fluvastatin, Couvert and co-
workers reported that the SLCO1B1 variant, P155T (rs11045819) reduced LDL in the 
patients with the CC genotype  more than in  CA and AA genotypes (Couvert et al. 2008). In 
the Cape Admixed, this variant demonstrated a MAF at 19.2% which was higher than 
Colombian (14.9%) and British (15.4%) populations. 
 
 
 
 
 66 
 
The intronic SNP rs4149036 was identified to be linked with triglyceride lowering in 
atorvastatin treated individuals with the uncommon homozygous AA (Thompson et al. 2005). 
This study found that the MAF for this variant was 26.5% which was a bit higher than that in 
Colombians (25%). 
The SLCO1B3 S112A (rs41429117), has been shown to increase transporter activity in vitro 
(Letschert et al. 2004). The T allele of S112A in Italians and Hungarians was observed at 
29.4% and 47.8%, respectively (Nagy et al. 2015). It was detected in Chinese (35%), Malay 
(20%) and Indians (8%) in a study by Chew et  al. (2011) and 15% in Caucasians (Baker et 
al. 2009). However, in the present study this variant was observed with a MAF of 18.5%. 
In a study of HeLa cell lines, V560A (rs12299012) in SLCO1B3 showed reduced uptake 
activity for rosuvastatin compared to the wild-type (Schwarz et al. 2011). To our knowledge, 
clinical data is currently lacking for the variant T147A (rs57585902). However,  this SNP and 
V560A (rs12299012) were not observed in Chinese, Malays and Indians (Chew et al. 2011) 
which corresponds with our population, British, Hispanic and Gujarati Indian populations. 
Both variants were observed in Caucasians with a MAF of  0.5% and 1.6%, respectively 
(Baker et al. 2009). 
The variant G256A (rs60140950) associated with the expression of SLCO1B3 gene was 
reported to have a negative effect on protein function in Caucasian Europeans (Geraldine et 
al.). Chew and colleagues also investigated the variant G256A (rs60140950) and it was found 
in Malays and Indians with MAF of 4% and 5%, respectively, but not in Chinese (Chew et al. 
2011). Similarly, a previous study (Baker et al. 2009) detected  this variant in Caucasians 
with a MAF of 1.9% which roughly corresponded with our population result that showed a 
MAF at 2.3%. 
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The rare SLCO1B3 variant, G522C (rs72559743) is reported to decrease protein expression 
and reduce the transporter activity which may be because of its location in the key regions of 
the transporter OATP1B3 (Letschert et al. 2004; Schwarz et al. 2011). It is notable that there 
is no population data on this variant on the database. However, Letschert et al. (2004) 
detected this SNP in Caucasians with a MAF of 2%. Chew et al. (2011) did not observe it in 
Chinese, Malays and Indians populations. This allele was also not detected in our study of the 
Cape Admixed. 
The incorporation of haplotypes in pharmacogenetic studies is believed to provide a more 
complete picture of loci that are applicable in genetic medicine to determine individual or 
population response to relevant drugs (Crawford and Nickerson 2005). In our study 
represented here, the haplotype structure defined for the ten SNPs was determined for the 
Cape Admixed population. Twelve haplotypes were detected from the five SNPs in 
SLCO1B1 and four haplotypes were inferred from the five SNPs in SLCO1B3. This data of 
haplotype structure could provide the basis of more clinical and in vitro studies to determine 
a suitable dosage for individuals with high efficacy and low toxicity. 
3.5. Conclusion: 
To conclude, in this chapter, we have focused on particular genes (SLCO1B1 and SLCO1B3) 
which encode for transporters located on the basolateral membrane of hepatocytes. These 
transporters have a significant role in the transport of statins. SNaPshot assay was developed 
to genotype five SNPs in SLCO1B1 and five SNPs in SLCO1B3. The obtained results were 
compared to seven different ethnic groups. In addition, haplotypes were inferred from these 
genes. Studying solute carrier transporters (SLCs) genetic variations and their 
pharmacogenetics implications in African populations will fill the gap in the missing data of 
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pharmacogenetics. Pharmacogenetics can be a robust tool to investigate the effect of genetic 
differences in these genes and their impact on drug response.  
In the next chapter, we are going to discuss high resolution melt technique as an alternative 
genotyping system.  
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Chapter Four 
Development and performance evaluation of High Resolution Melt Analysis Genotyping 
System   
4.1. Introduction 
SNPs are commonly investigated as markers of genetic variation in pharmacogenetics studies 
of cancer and other complex diseases (Martino et al. 2010). During the past decade, many 
high throughput genotyping techniques have been improved and developed (Martino et al. 
2010). However, in the recent years it has been suggested that high resolution melt technique 
(HRM) is the most widely used technique in genome analysis (Martino et al. 2010). HRM is 
a cheap, fast and easy method to discriminate single base variations and small insertions and 
deletions (Druml and Cichna-Markl 2014; Prajantasen et al. 2015). HRM analysis was first 
introduced by Ririe et al. (1997). It is a real-time PCR-based technique for mutation and 
genotyping studies (Ezgu et al. 2014; Mastoraki et al. 2015). It is based on the principle that 
different PCR products vary in their melting temprature depending on the percentage of GC, 
length and sequence  (Druml and Cichna-Markl 2014; Prajantasen et al. 2015). HRM is ideal 
for SNP genotyping, however, it is not recommended for screening genes with highly 
variable SNPs (Vondráčková et al. 2015). Given that a HRM approach offers several, the aim 
of this part of the study was to develop an HRM-based method for genotyping SNPs 
associated with FDA approved anticancer and lowering cholesterol drugs in the Cape 
Admixed population. HRM performance was evaluated and compared with SNaPshot as it is 
the standard genotyping system which its results were confirmed by direct sequencing.  
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4.2. Materials and Methods 
4.2.1. Sample Collection 
Samples were collected as described in Chapter2. 
4.2.2. DNA Extraction   
Genomic DNA was extracted as described in Chapter 2. 
4.2.3. SNP Selection 
SNPs were selected as described in Chapters 2 and 3. 
4.2.4. Primer Design 
All primers were designed by using Primer3plus tool and synthesized by Inqaba Biotec, 
South Africa (Table 4.1). The amplicons were made with the size ranging from 154-280 bp 
then aligned at Ensembl using BLAST (http://www.ensembl.org/Multi/Tools/Blast). Primers 
were diluted to a working stock of 2 μM.  
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Table 4.1- A list of selected SNPs primers used in HRM analysis. 
 
Gene dpSNP ID 
 
Nucleotide 
Change  
 
Forward primer  Reverse primer  
Amplicon 
length 
 (bp) 
DPYD rs3918390 C/T TGCCAATTCTCTTGTTTTAGATG GACAAATGTTTCCCCCAGAA 195 
DPYD rs2297595 T/C GCGAAGGATTTCTGATCTGTG AATGTGCCCCATGAGTGTTT 278 
TPMT rs1800460 C/T TTACCATTTGCGATCACCTG TAAAACCATGAGGGGATGGA 265 
MTHFR rs1801133 G/A GAAAAGCTGCGTGATGATGA TGTTGGAAGGTGCAAGATCA 231 
TPMT rs1142345 T/C ATTTTATCTATGTCTCATTTACTTTTCTGT CATGTTACTCTTTCTTGTTTCAGGTAAAAT 154 
SLCO1B1 rs4149056   T/C TCTACATAGGTTGTTTAAAGGAATCTGG AAAGTAGACAAAGGGAAAGTGATCATAC 208 
SLCO1B3 rs60140950 G/C CACTATCAGAATAACTCCTAAGGACTCTC CTGACTCTAGATGATTTGAGTATGCTTTAT    343 
SLCO1B3 rs57585902 A/G CATCAGAAAATTCAACATCAAGTTTATC GGATAAATGTTCTTCCTATTTGTTCTTAAA 209 
SLCO1B1 rs11045819 C/A ATTAATCAAATTTTATCACTCAATAGAGCA GGGCGAACTGTGTATATTAACACTATAA 216 
SLCO1B1 rs2306283   G/A ATTCAGTGATGTTCTTACAGTTACAGGTAT AATTATGTCTGTAAGAGTCAAATGTTTTTC 280 
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4.2.5. HRM Analysis 
HRM was done using the KAPA HRM FAST PCR kit. The final reaction volume of 20 µl 
contained 15 ng of DNA and was set up according to manufacturer’s instructions. HRM 
analysis was performed on a 36-well Rotor Gene Q (Qiagen) real-time PCR thermocycler. 
Thermocycling conditions were: initial hold at 95°C for 3 min, followed by a total of 40 
cycles of denaturation at 95°C for 5 sec, annealing at 63°C for 20 sec and extension at 72°C 
for 30 sec with fluorescence acquisition, then HRM was performed over a melting 
temperature ranging from 70°C-95°C at the rate of 0.1 °C per sec. Melt profiles were then 
analysed using the Rotor Gene data collection software (Qiagen). 
 
4.2.6. HRM sensitivity: 
HRM sensitivity was calculated by the number of genotypes obtained over the total reactions 
(Martino et al. 2010), while error rate was calculated as the number of genotypes different 
between HRM and SNaPshot divided by the number of genotypes obtained by HRM (Cui et 
al. 2013).  
4.2.7. Sequencing analysis: 
Direct sequencing was used to validate SNaPshot genotyping results, which the later was 
used to evaluate and validate the HRM performance as a standard for genotyping. 
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4.3. Results: 
4.3.1. PCR and HRM optimization: 
 
4.3.1.1. Optimizing annealing temperature: 
Firstly, all primers sets needed to be optimized to determine an appropriate annealing 
temperature (Ta). Therefore, gradient PCR was performed for each primer set and any 
resultant amplicons were analyzed by 2% agarose gel electrophoresis. Figure 4.1 showed the 
result of optimizing annealing temperature for the SNP rs60140950 HRM primer which the 
bands had quite similar brightness. However, the annealing temperature at 63 gave the best 
result. 
 
 
Figure 4.1-Anneaing temperature optimization of the SNP (rs60140950) by gradient PCR on 2% agarose gel.  
1: at 58°C, 2: at 59°C, 3:  at 60°C, 4: at 62°C, 5: at 63°C. 
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4.3.1.2. Optimizing MgCl2 concentration: 
MgCl2 concentration was the main factor that affected our results. Five concentrations of 
MgCl2 (2.5mM, 3.5mM, 5mM, 7.5mM and 10mM) were tested. However, the best result that 
could discriminate heterozygote samples was 10mM MgCl2 (Figure 4.2).  
 
Figure 4.2-MgCl2 optimization of the SNP (rs60140950) on 2% agarose gel. 1: 2.5mM, 2.5mM, 3: 7.5mM, 4: 
10 mM. 
 
4.3.2. Genotyping: 
The homozygotes samples of the investigated SNPs rs3918290, rs1800460, and rs57585902 
were detected easily. However, no heterozygotes samples for the SNPs rs1801133, 
rs1142345, rs11045819 and rs60140950 were able to be discriminated. They were detected 
only for the SNPs rs4149056, rs2306283 and rs2297595 (Figure 4.3).  
As shown in Figure 4.3, for the SNP rs1801133, the wild type G and the mutant A were  
detected on the HRM mutation scan, however, the melting temperature (Tm) of the mutant A 
was slightly shifted to the left compared to  the wild type G, and the reason of that is AT base 
pair had a lower melting temperature compared to a GC base pair (Cui et al. 2013). 
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Figure 4.3- HRM mutation scan for SNP rs1801133. The wild type G and mutant A can clearly be 
distinguished. 
In Figure 4.4 A and B, heterozygosity in the SNPs rs4149056 and rs2306283 is clearly 
detected as their peaks were much lower and wider than the peaks for the homozygote 
samples. 
 
Figure 4.4 A- HRM mutation scan of SNP rs4149056. The homozygotes and heterozygote peaks can be clearly 
distinguished based on peak height. 
 
 
 
 
 
 
 76 
 
 
Figure4.4 B- HRM mutation scan of SNP rs2306283. The homozygotes and heterozygote peaks can be clearly 
distinguished based on peak height. 
4.3.3. Evaluation of SNaPshot and HRM systems: 
We compared sensitivity of HRM with the SNaPshot assay which was confirmed by direct 
sequencing (Table 4.2). HRM sensitivity, defined as the number of genotypes obtained over 
the total number of reactions (Martino et al. 2010), while error rate was calculated by taking 
the number of genotypes different between HRM and SNaPshot divided by the number of 
genotypes obtained by HRM (Cui et al. 2013). 
The data represented here showed a mean level of HRM sensitivity of 89.2%, while the mean 
error rate was 20.8 % (Table 4.3). The difference in HRM sensitivity which was 
demonstrated in this study could be attributed to several factors. However, some previous 
studies showed that the sensitivity of HRM was affected by the instrument type (De Leeneer 
et al. 2008; Herrmann et al. 2007; Cui et al. 2013). The differences detected in this study 
could be due to performing the reactions on a capillary system which is less sensitive than 
newer micro-titre plate systems. 
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Table 4.2-Confirmation of SNaPshot genotyping using direct sequencing 
 
SNPs 
 
Number of samples 
 
Correct SNaPshot genotypes 
 
*Error rate % 
rs2297595 130 126 3.2  
rs1801133 130 127  2.4 
rs1142345 130 130 0 
rs1800460 130 130 0 
rs3918390 130 130 0 
rs4149056 130 121 7.4  
rs60140950 130 126 3.2  
rs57585902 130 130 0 
rs11045819 130 130 0 
rs2306283 130 130 0 
*Error rate = number of genotypes different between SNaPshot and direct sequencing/number of correct 
genotypes obtained by SNaPshot. 
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Table 4.3- Performance of HRM in comparison to SNaPshot. 
 
(a)
Sensitivity = number of genotypes obtained/total reactions 
 (b)
Error rate = number of genotypes different between HRM and SNaPshot /number of correct genotypes obtained by HRM. 
AA = Homozygous for the ancestral allele, AB= Heterozygous, BB= Homozygous for the minor allele.
 
dp SNP ID 
 
Type of drug 
 
Total samples 
 
Correct profiles 
(a)
Sensitivity % Error rate  
Error rate% HRM SNaPshot Err/AA Err/AB Err/BB 
rs2297595 Anticancer 50 49 98 96.9 0/47 1/3 0 2.1 
rs1801133 Anticancer 50 38 76 97.7 5/25 7/7 0/18 31.6 
rs1142345 Anticancer 50 48 96 100 0/48 2/2 0 4.2 
rs1800460 Anticancer 50 50 100 100 0/50 0 0 0 
rs3918390 Anticancer 50 50 100 100 0/50 0 0 0 
rs4149056 Cholesterol lowering 50 44 88 93.1 0/44 5/6 0 11.1 
  rs60140950 Cholesterol lowering 50 49 98 96.9 0/49 1/1 0 2 
 rs2306283 Cholesterol lowering 50 32 64 100 0/21 18/22 0/7 56.3 
   rs11045819 Cholesterol lowering 50 36 72 100 0/36 14/14 0 38.9 
   rs57585902 Cholesterol lowering 50 50 100 100 0/50 0 0 0 
  Mean 44.6 89.2 98.5    20.8 
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4.4. Discussion: 
Numerous techniques are developed for SNP genotyping; however, HRM assay are less time 
consuming, easy and cheap method (Reed and Wittwer 2004; Erali et al. 2008). In addition, it 
does not require any post PCR steps, as it is done in one tube or plate (Wittwer et al. 2003; 
Norambuena et al. 2009). In comparison with SNaPshot that needs minor optimization, HRM 
has been described as an uncomplicated method which can detect several SNPs in one 
multiplex assay (Pati et al. 2004). In addition, it is reliable, rapid and accurate (Syvänen 
1999). Despite that, it is more expensive than other methods (Pati et al. 2004). 
 The aim of this present study was to develop and explore an inexpensive, fast and alternative 
method to genotype different SNPs associated with anticancer and cholesterol lowering 
drugs, and to evaluate and validate the data obtained from HRM by comparing it with the 
SNaPshot system which is considered the gold standard for genotyping. In this study, five 
SNPs related to anticancer drugs and five SNPs related to cholesterol lowering drugs were 
selected to be amplified and analysed individually and a total of 50 samples were genotyped 
for each SNP. Several factors such as amplicon size, MgCl2 concentration and DNA quality 
were taken into consideration in order to successfully performed HRM assay on the selected 
SNPs.  
It has been shown that HRM is more sensitive when small amplicons are used because the 
differences in the melting temperature (Tm) are greater compared to larger amplicons 
(Gundry et al. 2008). However, genotyping SNPs by HRM with larger products (amplicon 
size of 600 to 1000 bp) has been reported  (Reed and Wittwer 2004). Thus, in this study, 
primers were designed to generate the shortest possible amplicons flanking the mutation of 
interest with high efficiency, low template secondary structure, and low complementarity. 
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After determining the optimal conditions, HRM was successfully performed. Genotype for 
each SNP was determined after the melting peaks were normalized. Heterozygotes are easily 
distinguished by a change in shape and width of melting curve (Graham et al. 2005; Cui et al. 
2013; Gundry et al. 2008), while homozygotes could be identified by a shift in melting 
temperature (Cui et al. 2013), which is in our study differed by approximately 0.5°C. The 
homozygous SNPs detected in this study were class 1 (G/A, C/T), class 2 (C/A) and class 3 
(C/G). In a study by Liew et al., reported that about 4% of homozygous human SNPs  of 
class 3 and class 4 (T/A) cannot be detected by HRM due to the small difference in melting 
temperature (Tm) generated by homozygous T/A and C/G base pairs (Liew et al. 2004).  
4.5. Conclusion: 
In this chapter, HRM was used as an alternative, inexpensive and rapid methodology to 
genotype five SNPs related to anticancer drug therapy and five SNPs related to cholesterol 
lowering drug therapy (statins). A rigorous optimization was required for the detection 
heterozygous genotypes. The obtained SNaPshot results were confirmed by direct sequencing 
to use them as a standard for evaluating HRM performance. 
 Ultimately, this study found that the SNaPshot assay was the more appropriate method as it 
needed minor optimization compared to HRM. 
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Chapter five 
Conclusion 
SNPs are the most prolific type of variations in the genome, and have been used as molecular 
markers in a wide range of studies. A number of SNP genotyping technologies have evolved 
in the last few years. In genetic research, development of new techniques for high-throughput 
SNP analysis is one of the most stimulating areas with regards to using SNPs, particularly in 
studies of normal and pathogenic human variations. Despite the remarkable technological 
advancements, further improvements are still necessary which must focus on the 
development of cost effective and less time consuming methods. Therefore, progress in 
genotyping methods is essential for the development of precision medicine as these 
technologies will advance the healthcare industry and contribute to the evolution of medical 
science. 
African populations have the most genomic diversity in the globe. However, in spite of being 
the origin of all the modern human beings, genetics studies on these ethnically diverse 
populations is still limited. In particular, South Africa is home to different ethnic groups from 
Europe, Asia and Africa. The mix of these groups led to the establishment of a unique 
population called South African coloured population, which are distinguished in this study as 
the Cape Admixed. Intensive studies on the genomic diversity in Africa and particularly in 
South Africa should be made, which could compensate for the lack of pharmacogenetics data 
that might have significant medical implications and serve as a solution for the wide health 
burden in this continent. 
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In this study, we have developed a SNaPshot and a HRM assay for pharmacogenomics 
profiling. The performance of both genotyping systems was evaluated using direct 
sequencing.  
Ten SNPs associated with anticancer therapy were genotyped in 130 individuals within the 
Cape Admixed population. The results obtained were compared globally to seven different 
ethnic groups which were: British in England and Scotland (GBR) who served as 
representative European Caucasian; Colombian in Medellin, Colombia (CLM) and Mexican 
ancestry in Los Angeles, California (MXL) who both represented admixed populations; 
Gujarati Indian in Houston, Texas (GIH) represented Asians, while African ancestry in 
Southwest USA represented African Americans (ASW); and Luhya in Webuya, Kenya 
(LWK) and Yoruba in Ibadan, Nigeria (YRI) both served as representatives of sub-Saharan 
African populations.  
In addition to anticancer drugs profiling, five SNPs of SLCO1B1 and five SNPs of SLCO1B3 
associated with cholesterol lowering drugs were investigated and the data obtained was also 
compared to the seven different ethnic groups. The haplotype structures were inferred for the 
SLCO1B1 and SLCO1B3 genes. From the obtained results, as expected the Cape Admixed 
population shares genetic characteristics with several other global populations.  
A SNaPshot minisequencing system was successfully designed, developed and used to offer a 
quick, high throughput and accurate technique that required minor optimization. HRM 
method was designed and used to genotype five SNPs related to anticancer drugs and five 
SNPs related to cholesterol lowering drugs. The performance of HRM was evaluated by 
comparing with the SNaPshot assay results as it is the gold standard genotyping technique. 
Both assays were validated using direct sequencing. Despite its advantages - closed tube, 
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cheap and rapid method for identifying genetic variations, HRM is more time consuming  to 
optimize and may require primer redesigning as well as optimization of reaction conditions. 
In future research, we suggest exploring the use of the MassARRAY
®
 System (Agena 
Bioscience) for pharmacogenomics SNPs genotyping. This system combines mass 
spectrometry, a sensitive and robust chemistry, and advanced data analysis software to meet 
the assay design, validation, and performance needs of genomic laboratories. In addition, the 
developed genotyping systems could be further validated using clinical samples from 
patients. This could help in optimizing drug therapy for cancer and cholesterol.  
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